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Abstract
CAPTURE AND CHARACTERIZATION OF DIOXYGEN REACTIVE INTERMEDIATES IN CYP51 CATALYSIS
By Gareth K. Jennings
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2013.
Director: John C Hackett, Assistant Professor, Department of Medicinal Chemistry.

The cytochromes P450 (CYPs) are a superfamily of biological catalysts that are
ubiquitous throughout the biological domain. CYPs are heme-b containing monooxygenases which oxidize substrates with the help of accessory redox partners. CYP
substrates include endogenous compounds required for many biological functions and
homeostasis, such as steroids, as well as the majority of clinically used drugs and
environmental xenobiotics. The majority of studies that have been performed to date
are on P450cam (CYP101) from Pseudomonas putida. Of the numerous reactions
catalyzed by CYPs, unactivated carbon-carbon bond cleavage, is one of particular
versatility. Being unique in their catalytic mechanisms, the C-C bond cleaving enzymes
and in particular CYP51 from Mycobacterium tuberculosis are though to be capable
of utilizing multiple reactive oxygen intermediates. During the process of C-C bond
cleavage, CYP51 catalyzes two classical hydroxylation reactions. The final reaction
culminates in an enigmatic third step which cleaves a C-C bond, liberates formate, and

x
installs a 14,15 double bond within its steroid substrate. The mechanism of CYP51s
final step is still unclear and the exact activated oxygen species has yet to be observed.
CYP51 is also distinct from most CYPs owing to the fact that the acid functionality
of the conserved active site “acid-alcohol pair” found in most CYPs, is replaced by a
histidine. This study aimed to trap and characterize dioxygen reactive intermediates,
and elucidate the role of the unique acid-alcohol pair in the formation and stabilization
of these intermediates. This study demonstrates our success in generating, stabilizing,
and spectroscopically characterizing reactive dioxygen intermediates in Mtb CYP51.
As the life-time of the oxyferrous intermediate in Mtb CYP51 is extremely short
at ambient temperatures, this work has shown the laboratory’s expertise in being
able to generate reduced oxyferrous intermediates at cryogenic temperatures. These
intermediates have only been generated in a handful of cytochromes P450 and as such
this work adds critical information to the small body of work currently reported.

1

Introduction

1.1 The Cytochromes P450
1.1.1 Background
The cytochromes P450 (CYPs) are a superfamily of biological catalysts that are ubiquitous throughout the biological domain. CYPs are heme-b containing monooxygenases
which oxidize substrates with the help of accessory redox partners. Using two reducing
equivalents, the CYPs are capable of catalyzing oxygen atom insertion into otherwise
unactivated C-H bonds of a substrate (R-H) [1] by the reaction:

R − H + O2 + N AD(P )H + H + → R − OH + H2 O + N AD(P )+

(1.1)

The term “cytochrome” refers to proteins that contain a heme prosthetic group
that participates in electron transport. In cytochromes P450, “P450” refers to pigment
that absorbs at 450 nm in the UV-visible (UV-vis) spectrum following reduction and
binding to carbon monoxide [2]. This terminology is still used today even though
the preferred naming by the Nomenclature Committee of the International Union
of Biochemistry (NCIUB) nomenclature is in fact, “heme-thiolate protein” [3]. The
nomenclature applied today, as summarized by Nebert [4, 5], designates the CYP by
its gene family denoted by a number, subfamily (if there are more multiple subfamilies)
denoted by a letter, and individual gene denoted by a number. The arbitrary cutoﬀ
of amino acid identity required for a CYP within a particular family is 40% and
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within a particular subfamily is 55% [5]. The enzyme CYP3A4, for example, is part
of the CYP3 family, which plays a role in drug and steroid (including testosterone)
metabolism. CYP3A4 is also part of the only subfamily of the CYP3 family, namely
subfamily A and is expressed from a human gene, denoted in this particular example
as 4.
The superfamily can be divided into two classes, based on their electron donor
proteins. Type I CYPs are mitochondrial/bacterial proteins which acquire electrons
from an iron-sulfur ferredoxin containing an [Fe-S] cluster which has been reduced by
an NADH-dependent FAD-containing reductase. All drug and xenobiotic metabolizing
proteins are Type II CYPs which utilize an FAD-FMN to reduce a NADPH-cytochrome
P450 reductase, which in turn shuttles electrons to the CYP [6]. In both classes,
interaction with the CYP and its electron donor is a prerequisite for catalytic activity.
CYP substrates include endogenous compounds required for many biological
functions and homeostasis, such as steroids, as well as the majority of clinically used
drugs and environmental xenobiotics. As much as 75% of all known drugs encounter
CYPs at some point during their metabolism in humans [7, 8]. The documentation
and understanding of xenobiotic metabolites is of great importance, owing to the fact
that metabolites can be toxic and carcinogenic.
1.1.2 The Cytochrome P450 Catalytic Cycle
As previously stated the in Section 1.1 the CYPs are capable of activating O2 to a
number of reactive oxygen species capable of oxidizing their substrates. The CYPs
utilize an iron protoporphyrin IX with a cysteine thiolate axial ligand. As depicted in
Scheme 1.1, A the resting state of the enzyme is widely accepted as the aquaferric
species (the iron is in the ferric (Fe3+ ) form, and is hexacoordinated with a water
molecule as a ligand). In general, as the substrate binds to the enzyme (Scheme 1,

3
RH) , the water molecule is displaced and the spin state shifts from a hexacoordinated
low-spin (LS) state (S = 1/2) to a pentacoordinated high-spin (HS) state (S = 5/2)
(Scheme 1.1, B) . This spin shift is accompanied by an increase in the redox potential
of the enzyme. In the case of camphor binding to P450cam, the redox potential
shifts from -300 mV to -170 mV [9, 10]. In the case of CYP51 from Mycobacterium
tuberculosis, upon binding estriol, the potential shifts from -375 mV to -225 mV [11].
The ligand-induced shift in spin-state results in a shift of the Soret from 412 - 417 nm
in the LS form to 391 - 395 nm in the HS form [1]. The change in conformation of
the enzyme on ligand binding has also been implicated in the increased aﬃnity of the
P450 for its redox partner [12].
The increase in redox potential aﬀords the first electron transfer from nicotinamide
cofactors(NADH or NADPH). This results in the reduction of the heme iron from
Fe3+ to ferrous (Fe2+ )C (Scheme 1.1). It is at this point of the cycle that O2 binds
to the P450 (Scheme 1.1, D). It is speculated that the this species (Fe2+ -O2 ) has
another resonance form (Fe3+ -O2 − ) [13, 14] in P450cam. It is important to note that
all the species to this point of the catalytic cycle have been observed and characterized
experimentally, without excessive challenges in the laboratory.
At this point the oxyferrous species is capable of accepting another electron from
its redox partner and forms a ferric peroxo species (Fe3+ -O2 2− ) (Scheme 1.1,E), which
is in turn able to accept a proton and form the hydroperoxo ferric species (Scheme
1.1, F) also known as Compound 0 (Cmpd 0). Cmpd 0 is capable of undergoing a
second protonation that cleaves the O-O bond releasing water to yield a high-valent
iron-oxo complex G (Scheme 1.1) known as Compound I (Cmpd I) [15–19]. Cmpd I
is an oxoferryl π-cation radical species and is considered to be the most prominant
oxidant in CYP catalysis and is recognized as nature’s most powerful oxidant. Cmpd I
mediates the hydroxylation reaction via a hydrogen atom abstraction/hydroxyl radical
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rebound mechanism (Scheme 1.1, H) [20]. As the hydroxylated product leaves the
active site, it is replaced by a water molecule completing the cycle and regenerating
the resting state enzyme.
The catalytic cycle also has three pathways known as uncoupling pathways, which
are unproductive with regards to hydroxylation of substrate and ultimately result in
the return of the enzyme to the ferric resting state. The first uncoupling is referred to
as “autoxidation” (Scheme 1.1, 1) and occurs when the oxyferrous species (Scheme
1.1, D) undergoes a release of a superoxide anion (O2 .− ) [21]. The second uncoupling
occurs when peroxide is released from Cmpd 0 known as a “peroxide shunt”(Scheme
1.1, 2). Cmpd I is also capable of undergoing a shunt referred to as the “peroxidase
shunt” (Scheme 1.1, 3) and occurs when the oxo-ferryl species undergoes two electron
reductions with concomitant protonation of the oxygen, resulting in the aquaferric
species. The majority of the uncoupling reactions that occur are autoxidations as
result of no substrate being present in the active site [22–24].

1.2 Cytochrome P450 Structure
1.2.1 Ligand Recognition and Binding
The majority of studies that have been performed to date are on P450cam (CYP101)
from Pseudomonas putida owing largely to the fact that it was the first CYP that
could be purified in large enough quantities for such studies as it was soluble and highly
expressed in P. putida. The first crystal structure of CYP101, solved by Poulos [25] in
1985, contributed greatly in the understanding of the active site structure of CYPs.
In the last decade, numerous crystal structures have permitted larger generalizations
to be made about CYPs with regard to overall structure and active-site architecture.
When comparing the crystal structures of these enzymes, it is evident that although
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there is generally low sequence homology (∼ 20%) between members of the CYP
superfamily all exhibit similar topology and overall fold [26, 27]. The CYP fold can be
divided into α-helical and β-strand-rich domains as seen in Figure 1.2. The inner core
of the protein is made up of the N-terminal half of the protein which wraps around
the heme and C-terminal half. However, the N-terminal begins in the β-domain
(Figure 1.2) and crosses into the helical domain after which as it follows the I-helix it
returns to the β-domain [28]. This criss-crossing of the polypeptide has implications
in the folding of the protein and incorporation of the heme prosthetic group, since the
entire polypeptide must be released from the ribosome prior to protein folding, which
complicates expression of the protein in non-native environments [29].
The conserved structures include 11 α-helices (A-K) as well as 5 pairs of β-strands
in antiparallel conformation. The variations in the length and shape of these secondary
structural elements, aﬀords the variable architecture of the CYP superfamily active
sites. This in turn allows for promiscuity in substrate recognition and the diversity
of the reactions catalyzed by the enzymes. There are six sites in the CYP structure
that are important for substrate recognition and binding known as the “substrate
recognition sites” (SRS1-6). The first SRS is found in the loop between the B and
C helices (SRS1) and is positioned over the heme. The second and third sites are
in segments of the F (SRS2) and G helices (SRS3) which are involved in allowing
substrate access to the active site as well as interactions with the membrane, if the
enzyme is membrane associated. Another protein segment found to extend over the
heme pyrrole ring is part of the I helix (SRS4). The β-turn of the β4 (SRS5), and the
K helix-β2 loop (SRS6) are also involved in substrate recognition [30]. These regions
confer specificity for substrates and have been shown to drastically alter specificity
when mutated [31]. This is also evident in naturally occurring variations as seen in
CYP2A4 (testosterone hydroxylation) and CYP2A5 (coumarin hydroxylation), from
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the mouse, which diﬀer only in a few amino acids in SRS2 [32–35].
The environment immediately surrounding the heme, which includes the D, E, L
and I helices, is the most strongly conserved among members of the CYP superfamily
[22,36]. The heme group is is found between the I and L helices and is bound to a loop
which has a conserved sequence -Phe-Xaa-Xaa-Gly-Xaa-(His/Arg)-Xaa-Cys-Xaa-Gly-,
where the Cys is the cysteine-thiolate which contributes the fifth ligand of the iron of
the iron-protoporphyrin IX heterocycle. Prior to the availability of any CYP crystal
structures, Dawson confirmed the cysteine-thiolate ligand using magnetic circular
dichroism (MCD) spectroscopy [37]. This Cys is critical in mediating CYP chemistry.
Structurally, the peptide NH of this Cys residue donates an anti-parallel β strand
type hydrogen-bond with an oxygen of the carbonyl of an adjacent residue [25, 28].
This helps form an environment that orients the Cys amongst multiple peptide NH
groups with no hydrogen-bond acceptors other than that of the Cys-thiolate as shown
in Figure 1.1. These hydrogen-bonds between the peptide NH’s and Cys-thiolate
are generally accepted as being needed in order to modulate the redox potential
of the Fe. With hydrogen-bonds being donated to the Cys, its negative charge is
decreased, eﬀectively increasing the redox potential of the system, allowing NAD(P)H
or other reductants to reduce the Fe [38, 39]. It is speculated that if these peptide
NH hydrogen-bond donors were not present, the Fe would remain in the oxidized
Fe(III) state. Density Functional Theory (DFT) calculations have confirmed the
ability of these hydrogen-bonds to play a role not only in redox potential of the Fe
but also in tuning the reactivity of Cmpd I. The thiolate exhibits radical character
during the formation of Cmpd I in these calculations [40]. On the addition of a
hydrogen-bond donor to the Cys-thiolate of the model, the radical character shifts to
the the porphyrin, this in turn, increases the reactivity of Cmpd I [41, 42].
Another conserved feature amongst CYPs is the disruption of the α-helical

8

Figure 1.1: The cysteine thiolate ligand loop of CYP101. Arrows point to the
peptide N that are oriented around the cysteine thiolate. Dotted lines represent
hydrogen bonding.
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hydrogen-bonding in the I-helix. This disruption or “kink” occurs near the conserved“acidalcohol” and creates an opening required for solvent accessibility [43]. Both the
distortion in the I-Helix and the resulting solvent accessibility are required in O2
activation. In the case of CYP51, it too has a “kink” in the I-helix, however there it
is unique in that the I-helix is bent by ∼45 degrees [44], which has been implicated as
an alternative opening for substrate binding and product release.
1.2.2 The CYP Active Site
When the first crystal structure of CYP101 was published by Poulos [25] in 1985,
it became evident that no residues could be definitively assigned as playing a role
in proton conduction to the active site [10] as the residues were predominantly
hydrophobic and no apparent acid-base catalytic residues were present. It would
take alignments of multiple CYP amino acid sequences to determine that within
the P450 superfamily two highly conserved residues were present [5, 45]. These were
two sequential amino acids that have become known as the conserved“acid-alcohol
pair” of the P450 superfamily. In CYP101, Asp251 and Thr252 are oriented directly
over the heme plane in the I-helix (Figure 1.4). The “kink” of the I-helix, brought
about by the loss of α-helical hydrogen-bonding consists of the conserved sequence
-Gly-Gly-Leu-Asp-Thr-. Together, these conserved sequences play a critical role in
CYP molecular oxygen activation and catalysis. A number of mutations aimed at
the acid-alcohol pair have revealed insight into their function. Due to the Asp251
and Thr252 residues’ ability to transfer protons, as well as their close proximity to
the heme, it was prudent to determine the role of these amino acids in stabilizing
the oxygen complex and mediating proton transfer to the peroxo anion, as shown in
Figure 1.5.
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Figure 1.2: A) The general topology of CYP101 (PDB:1DZ8) with helical and β
domains. B) Pipe and Plank rendering of CYP101 (PDB:1DZ8). Letters label α
helices A through K of the protein with arrows pointing in the direction of N-terminus
to the C-terminus.
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Figure 1.3: Substrate Recognition Sites (SRS) 1 through 6 of the CYP101 crystal
structure (PDB:1DZ8). SRS are colored in Purple
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Figure 1.4: The active site structure of CYP101 (PDB:1DZ8), with its subtrate,
camphor, bound in the presence of the O2 bound ferrous heme.
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Figure 1.5: A)Schematic of the proposed role of the acid-alcohol pair of CYP101.
B) Schematic of uncoupling in the Thr252Ala mutant of CYP101.
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When Thr252 was mutated to an Ala an uncoupling of the catalytic cycle occurred,
with no evidence of the hydroxylated product (camphor to 5-hydroxycamphor)[46, 47].
However, CYP101 was still capable of accepting two reducing equivalents from NADH,
without any significant change to the kinetics of both electron transfer steps. The
uncoupling was a result of the enzyme’s inability to cleave the O2 bond and ultimately
lead to the release of hydrogen peroxide [47]. These results were explained by the
authors in the crystal structure of the mutant [47] where a new water molecule was
found to hydrogen-bond to the backbone N-H of the Thr252Ala residue. This was said
to play a role in destabilizing the oxyferrous complex. In other mutagenesis studies
[48, 49] when Thr252 was replaced with a residue capable of hydrogen-bonding (such
as Ser) the extent of uncoupling was diminished. Regardless of the size of the mutant
sidechain or its pKa the requirement was not proton transfer but rather, its ability
to hydrogen-bond with a potential secondary proton donor [22]. Unnatural amino
acids have also been utilized to study the role of Thr252, with a Thr252Thr-O-methyl
being incorporated into the protein, which retained the ability to hydroxylate camphor
[50]. This work implied once again that Thr252 was not directly transferring protons
to the peroxoanion intermediate, but rather maintaining a water molecule network
that was involved in transferring protons. This work however did not address the
ability of CYPs to demethylate substrates, potentially removing the methyl group
of the unnatural methoxy-Thr eﬀectively rendering the wild type enzyme [10, 22, 51].
In CYP107, this alcohol functionality is not present and is replaced by an Ala. In
the crystal structure of CYP107 shown in 1.6 it was seen that an OH of the ligand
6-deoxyerythronolide B (6-DEB) was oriented such that it provided the only direct
hydrogen-bond to the distal O2 atom. It was speculated that this OH of 6-DEB was
the most likely candidate as the direct proton donor to the peroxo species [52, 53], in
a process referred to as“substrate-assisted catalysis” [54, 55]. This mechanism was
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further substantiated by mutation of this Ala to a Thr [55], resulting in loss of product
formation (thought to be due to the overlapping of the respective hydroxyls) however
the mutant enzyme was now capable of metabolizing other substrates it was previously
unable to [10, 56].
The acid residue Asp251 had also been implicated in proton transfer during
catalysis, however mutagenesis studies revealed that the role of Asp251 is diﬀerent to
that of Thr252. The bio-isosteric Asp251Asn mutant of CYP101 showed a decrease
in the rate of electron transfer from NADH, however 5-hydroxycamphor formation
was still occurring, albeit slower, and was shown to be due to the decreased rate
of the second electron transfer as well as proton transfer after the formation of the
oxyferrous complex [57]. The Asp251Ala and Asp251Gly mutants also produce a
similar phenotype to the Asp251Asn mutant [49], implying that the chemical properties
of the side chains are less important. Kinetic solvent isotope eﬀect (KSIE) studies of
the Asp521Asn mutant [58] showed a drop in turnover by ∼5 fold as a result of D2 O
addition, implying proton transfer from solvent is the rate limiting step in catalysis of
the mutant. In the same study, examination of the influence of pH on the mutant’s
catalysis was performed, with a linear increase in catalytic rates with the increase of
solvent protons being observed, pointing to bulk solvent being the proton donor. This
notion was strengthened by the observation of increased accessibility of bulk solvent
to the distal pocket due to new salt bridge contacts being formed in the mutant which
subjects the heme and distal pocket to greater access from outside of the protein
[22, 58]. Combined, these studies point to a general understand that the Asp251 plays
a critical role in proton transfer, either directly or indirectly.
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Figure 1.6: The structure of the acid-alcohol pair of CYP101 (blue, PDB:1DZ8),
with its substrate, camphor (gold), overlaid with the structure of CYP107 (magenta,
PDB:1Z8O), with bound 6-deoxy-erythronolide B (dark green). The double headed
arrows indicate the distances between the OH of Thr252 in CYP101 and the distal O
atom (3.47 Å) and the OH of 6-deoxy-erythronolide B and the distal O atom (2.73 Å)
of their respective structures.
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1.3 Carbon-Carbon Bond Cleaving Enzymes
1.3.1 Carbon-Carbon Bond Cleaving Reactions
Of the numerous reactions catalyzed by CYPs, unactivated carbon-carbon (C-C
hereafter) bond cleavage, illustrates the versatility of the CYP catalytic cycle. This
reaction is a critical step in many steroid biosynthetic pathways. These reactions
can require multiple passes through the catalytic cycle for C-C bond scission. The
C-C cleaving CYPs are capable of tuning the active site to use multiple reactive
intermediates. The final C-C cleavage step that is catalyzed can occur between two
oxygenated Cs, a C α to an oxygenated C and a C α to a C bearing an N. These final
scission steps can occur on substrates which already bear these chemical features or
these chemical groups could be a result of previous oxidations by the enzyme.
CYP11A1 (P450scc ) is a CYP which catalyzes the cleavage of the C20-C22 bond
of cholesterol resulting in pregnenalone, the common intermediate in steroid hormone
biosynthesis(Scheme 1.2 A) [59]. CYP11A1 performs two oxidations on the side chain
of cholesterol in typical fashion of CYP oxidation, first hydroxylating C22 of cholesterol
resulting in 22R-hydroxycholesterol. The second step hydroxylation step occurs on
C20 resulting in 20R,22R-dihydroxycholesterol as the product. The final step results
in the cleavage of the side chain between C20 and C22, releasing pregnenolone and
4-methylpentanal [60]. Mass spectrometry studies performed by Burnstein [61] in
bovine adrenocortical mitochondria preparations using cholesterol and
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environments showed the sequential oxidation of the C22 and C20 positions. As each
intermediate does not accumulate during catalysis, and both have higher binding
aﬃnities for the CYP11A1 than cholesterol, it is expected that these oxidations occur
in a sequential manner without the subtrate leaving the active site during each turn
of the catalytic cycle [62] and that there is increasing stability of the oxyferrous state
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with each intermediate [63]. While the first and second reactions are accepted to
proceed through the hydrogen atom abstraction/hydroxyl radical rebound mechanism,
the mechanism of the final step is poorly understood. Two mechanisms have been
proposed for this final step. The first would require the formation of a hydroperoxide
on one of the hydroxyl groups with a CYP activated oxygen intermediate, with this
intermediate undergoing heterolytic cleavage as a result of the other hydroxyl group
losing a proton, to form two keto-products (Scheme 1.2 B1). The second potential
pathway is the result of Cmpd I hydrogen atom abstraction from one of the hydroxyl
groups resulting in a radical species forming which causes a homolytic C-C cleavage to
occur forming a product with a hydroxyl group and a radical situated on the carbon,
and an aldehyde group. The Fe(IV)=OH will eﬀectively react with the radical forming
the other product (Scheme 1.2 B2) [1, 64].
Of particular mechanistic interest is CYP17A, a mammalian CYP involved in
pregnenolone and progesterone metabolism [65, 66]. During the metabolism of pregnenolone, the most favored pathway within this enzyme is the initial hydroxylation of
C17, followed by the attack of the C20 ketone by the ferric peroxoanion. Homolytic
cleavage of the of the peroxo O-O bond then occurs with concomitant release of
an acetic acid and formation of an alkoxy radical. Radical rebound occurs onto an
Fe(IV)O species with subsequent dehydration of the geminal diol complex resulting
in a ketone product (Scheme 1.3 B1) [67]. CYP17A is also capable of catalyzing
C17-C20 cleavage in pregnenolone through an alternative pathway, resulting in two
diﬀerent products (Scheme 1.3 B2). This pathway requires that pregnenolone does not
undergo the initial C17 hydroxylation, but rather peroxyanion attack of the carbonyl
C20 resulting in the release of acetic acid and a radical product. This can undergo
either oxygen rebound forming a hydroxylated product or a dismutation resulting in
an alkene product [67]. Mutation of the alcohol (Thr306Ala) of the acid alcohol pair in
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Scheme 1.2
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CYP17A[68], resulted in a drastically decreased formation of the initial hydroxylation
step of C17 in pregnenolone and is thought that this mutation disrupts the proton
delivery mechanism required for the formation of Cmpd I which is required in the
initial hydroxylation reaction [1, 64].
Two examples of enzymes which cleave C-C bonds adjacent to aldehydes are CYP51
and CYP19. Both are steroid biosynthetic enzymes which perform three sequential
oxidations in order to perform bond scission. As CYP51 will be discussed in more detail
in following sections, the focus will immediately shift to CYP19. CYP19 also known
as aromatase, catalyzes the aromatization of androstenedione to estrone (Scheme 1.4
A) [69–71]. Drugs targeting CYP19 in humans, called aromatase inhibitors, have been
developed for the treatment of estrogen-positive breast cancers [72, 73]. It should be
highlighted using CYP19 as a pertinent example that understanding the mechanistic
details of its specific catalytic pathway is critical for the design of such inhibitors. The
importance of this understanding extends to any CYP protein that could be considered
a therapeutic target, so as to develop drugs with high specificity and eﬃcacy.
In trying to understand the catalytic mechanism of CYP19 it is important to identify
the products of the three oxidative steps and their reactive oxygen intermediates
operative in each step. The aldehyde in Scheme 1.4 B1, is a good candidate for
oxidation by a ferric peroxide intermediate, this mechanism was used to rationalize
the observation of the fate of
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Akhtar and coworkers [74]. In summary their work showed that that formic acid
which is released in the third catalytic step bears oxygen atoms from the first and
third oxidation steps. This work is summarized in Scheme 1.5. This evidence allows
for a much smaller set of possible reaction mechanisms with the generally accepted
mechanism being the reaction of the ferric peroxide attack on the C19 carbonyl
yielding a peroxohemiacetal intermediate. This intermediate undergoes fragmentation
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forming an alkoxy radical, which ultimately is released as formic acid after enolization,
resulting in a C10 radical. After hydrogen atom abstraction of the 1βH, aromatization
occurs [1, 64, 75, 76].
Delving deeper into details pertaining to the exact Iron-oxo species performing
catalysis, Sen and Hackett, using molecular dynamics simulation and hybrid quantum
mechanics/molecular mechanics in combination with the recently published CYP19A1
crystal structure (PDB ID: 3EQM [77]) showed a kinetic advantage of one mechanism
(Scheme 1.4 B2) over that of any other proposed mechanisms, which supported the
formation of a peroxohemiacetal and C-C cleavage occurring as a concerted step,
after which formate is released. Cmpd II will perform hydrogen atom abstraction
followed by stereoselective enolization where Fe(III)-OH deprotonates the 2β-position.
The authors highlight key intermediates which would be experimentally observable
(within current laboratory means) and oﬀer explanations as to why the proposed
intermediates have yet to be observed due to such transient lifetimes. They also
highlight the role of critical amino acids in stabilization of catalytic intermediates.
These theoretical insights into CYP catalytic mechanism illustrate the synergism
aﬀorded by the cooperation between theory and experiment.
Numerous catalytic mechanisms have been proposed for the final catalytic step
of CYP19 [78–80]. The aldehyde which is formed through two turns of the CYP19
catalytic cycle (Scheme 1.4 A) has been generally accepted as being the intermediate
through which ferric-peroxo can oxidize the carbonyl carbon.
1.3.2 Sterol 14α-Demethylases as Models of C-C Bond Cleaving Enzymes
Of particular interest, within the group of CYPs catalyzing C-C bond cleavage, are the
sterol 14α-demethylases (CYP51). These homologs are among the most ubiquitous
and ancient of the CYP superfamily and found in the all biological domains [81–83]. As
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shown in Scheme 1.6, using dihydrolanosterol (DHL) as an exmple, it has been shown
that the reaction occurs in three turns of the catalytic cycle, each using one molecule
of O2 and two reducing equivalents supplied by NADPH. The first two turns of the
cycle are simple monooxygenation reactions, with the first product being a geminal
diol as seen in Scheme 1.6 and the second being a geminal diol. The geminal diol may
undergo a dehydration step ultimately resulting in an aldehyde product [74, 84, 85].
During the final step, formate is released and the 15α hydrogen atom is removed from
the substrate. The mechanism of this final step is still unclear and the exact activated
oxygen species has yet to be observed. Some mechanistic insight was provided by
studies conducted by Shyadehi and coworkers using Candida albicans CYP51 and
32-18 O and 32-16 O labeled aldehyde intermediates [84]. Unfortunately, however, a
number of catalytic mechanisms could be postulated that are consistent with the
observed isotope ditributions in the products. Although the proposed mechanism was
mediated by peroxo or Cmpd 0, there is still the possibility that the C-C cleavage
step may be Cmpd I mediated.

1.4 Mycobacterium tuberculosis CYP51 as a model of C-C bond cleaving
1.4.1 Structure
The sequencing and annotation of the entire genome of Mycobacterium tuberculosis
(M. tuberculosis, Mtb) strain H37Rv [86, 87] was an important step in determining
drug targets for this bacterial pathogen. The information acquired from this study
was the starting point for researchers to understand proteins within M.tuberculosis.
Sequencing revealed that M.tuberculosis genome codes for up to 20 putative Cytochromes P450, including a CYP51-like (gene Rv0764c). CYP51 is a known target of
azole drugs such as clotrimazole and fluconazole in the treatment of fungal infections,
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Figure 1.7:
A) The aligned crystal structures of the active sites of
CYP101 (blue PDB:1DZ8) and Mycobacterium tuberculosis CYP51 (magenta
PDB:1X8V) B) Alignment of the active sites of CYP51 from Leishmania infantum
(green PDB:3L4D), Homo sapiens (orange PDB:3JUV), Trypanosoma cruzi (blue
PDB:3KHM) Mycobacterium tuberculosis (magenta PDB:1X8V)
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with these drugs inhibiting the formation ergosterol, a necessary component in the
maintenance of the structural integrity of the fungal cell membrane [88–90]. What
was an important finding was that this was the first known prokaryotic CYP51. Mtb
CYP51 lacks an N-terminal membrane anchor of its eukaryotic orthologs simplifying
expression in bacterial expression systems. In 2000 Podust and coworkers published
the first crystal structure of Mtb CYP51 [44], making it the first crystal structure of
any C-C bond cleaving CYP. Using this crystal structure to align secondary structural
elements of other CYP51s, it was seen that 41 amino acids were conserved between
bacteria and animals [91]. Only three of these amino acids were conserved throughout
the entire CYP superfamily. It is also noted that the SRS2 and SRS4 regions are
highly conserved between species (Figure 1.7 B). The SRS4 should be noted for its
unique acid-alcohol pair, which in contrast to CYP101 (and the rest of the CYP
superfamily) does not have Asp or Glu in this position but rather His (Figure 1.7 A
and B) [44, 92]. As previously mentioned the acid-alcohol pair is implicated in playing
a critical role in oxygen activation and proton transfer. The diﬀerence in this proton
relay system poses questions as to how CYP51 activates molecular oxygen and tuning
the lifetimes of reactive oxygen intermediates.
1.4.2 Proton Relay and Oxygen Activation
The Hackett laboratory the studied proton shuttling and O2 activation in Mtb CYP51
catalysis using explicit solvent molecular dynamics (MD) simulations and hybrid quantum mechanics/molecular mechanics (QM/MM) [93]. The hypothesis that the His259
and Thr260 could relay a proton from bulk solvent to the peroxoferric intermediate
was tested by simulations of the histidinuim ion at the 259 position. Results of these
simulations showed the formation of two networks which relay protons to the peroxo
species. The first network, involving His-Thr dyad, was only capable of supporting
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Cmpd 0 formation, while the second proton transfer network connected the distal
O atom to Glu173 via four water molecules. In this configuration of the active site,
QM/MM calculations revealed that the oxyferrous species has a triradicaloid electronic
structure, resulting from protonation of Glu173. This triradicaloid structure has two
electrons (either parallel or unparallel) localized on the Fe-O unit and the third on
the protonated Glu173. Protonation of Glu173 resulted in polarization of electron
density allowing for the tunability of the reactivity of the peroxo intermediate. In
such a configuration the barrier for Cmpd 0 and Cmpd I formation is 2 kcal/mol
and 12 kcal/mol respectively. Glu173 is located in the F-helix surrounded by polar
residues and an easy access to bulk water making its transient protonation resonable.
The Hackett laboratory also went on to show using MD simulations that the
carboxaldehyde intermediate of DHL may divert the hydrogen-bonded network from
the O2 intermediate, in the final catalytic step [94]. This diversion promotes the
stability of the peroxo intermediate such that it is capable of attack on the C32
carbonyl. This in turn allows the peroxohemiacetal to form without an energy barrier
to overcome. The formation of this the peroxohemiacetal was determined to be a
branch point within the system (Scheme 1.7) with either protonation of this species
or C-C cleavage initiating the release of formate. In the proton-independent path, the
enzyme active site was seen to modulate the stability of the intermediates which could
be used to explain how CYPs are capable of a number of mechanistic pathways in
catalysis. Cmpd 0 and Cmpd I were found to be energetically unfeasible in this final
catalytic step.
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1.5 Significance
1.5.1 Tuberculosis
M. tuberculosis is a tubercle bacilli bacterial pathogen, which causes Tuberculosis (TB).
TB is a global health crisis, which is ever expanding, with 9 million new cases and
3 million deaths occurring each year [95, 96]. Approximately one third of the worlds
population has been infected by Mtb, however only about 10% of these cases will have
any clinical manifestations of disease. The cases, which remain asymptomatic, are
due to the equilibrium achieved between the hosts immune system and the pathogen.
Five percent of these asymptomatic cases will develop the active form of the disease
spontaneously due to immune suppression [95].
Tuberculosis has only one vaccine, known as BCG (bacillus of Calmette and Gurin)
and was prepared by repeated laboratory passage of an isolate of Mycobacterium
bovis until it no longer caused disease in humans [97]. BCGs eﬃcacy has been the
subject of much controversy due to highly variable protection in adults to pulmonary
tuberculosis. It was also apparent that protection varied with geographical distribution
and may be explained by the exposure of people to environmental mycobacteria. It
was concluded that the best responses to BCG were seen in people that had had no
prior exposure to mycobacteria and less of an eﬀect was noticed in people who had
been previously exposed to mycobacteria, which had resulted in acquired immunity
[98]. This theory is supported by the fact that protection by BCG vaccination in
children is not that variable, as children may have been vaccinated prior to major
exposure to environmental mycobacteria. When given to children who have not been
infected, BCG confers protection against the consequences of primary infection such as
pulmonary and meningitis tuberculosis [98]. It has also been speculated that certain
BCG vaccines have become over attenuated due to passage in the laboratory and
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this could have resulted in the deletions of segments of its genome. Potentially, the
over attenuated BCG could have lost its ability to illicit a host response by either
lacking key antigens or being unable to persist long enough in the host in order to
illicit an immune response [97]. BCG however confers protection to primary infectious
consequences such as spreading, but it does not prevent bacterial persistence and
reactivation of tuberculosis.
An individual can only be infected with tuberculosis by inhalation of an aerosolised
droplet containing M. tuberculosis. These droplets would be present in a person with
active disease. The bacteria would be found in the terminal air spaces of the lung
until they are engulfed by alveolar macrophages within which they replicate [98, 99].
M. tuberculosis uses multiple cell surface receptors in order to be phagocytosed by
macrophages. Within the phagosomal vacuole M. tuberculosis modifies the activity of
the vacuole in order to ensure its survival [100]. The colonization of the lung by M.
tuberculosis is partitioned into two major phases, namely the acute phase and the
chronic phase. The acute phase is characterised by the replication of the bacteria at
the initial site of pulmonary infection, which leads to the formation of a small lesion,
known as the Ghon Complex. The function of this Ghon complex is thought to allow
for reinfection through drainage in the lymphatic and blood systems, which usually
results in the infection of the apical regions of the lungs forming secondary lesions[101].
The hosts immune response however, usually controls the bacterial dissemination and
replication . The immune response is cell mediated and results from the activation
of macrophages by lymphokines released by lymphocytes in response to bacterial
antigens. This is known as Cell mediated immunity [102]. The hosts immune response
will ultimately lead to the formation of what are known as granulomas. The secondary
lesions, which form after dissemination from the granulomas, are a direct result of the
hosts immune response to the bacteria and are caseous (liquefied) granulomas due to
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tissue necrosis. Necrosis occurs due to the proteolytic enzymes being released by the
macrophages. Necrotic tissue has optimal pH (6.5) for M. tuberculosis growth however
the lack of nutrients such as amino acids, a carbon source and oxygen is thought to
cause non-replicating persistence or latency to occur [96]. M. tuberculosis can persist
in this latent form for many years without replicating but it has the potential to
resume growth and produce active tuberculosis [102].
The treament of Tuberculosis is dependent on eradication of latent tubercle bacilli
as well as prevention of reactivation of the disease. Current drugs, although eﬀective in
treating latent M. tuberculosis infections, do not prevent reactivation at a later stage of
an individuals life [103,104]. Azole antifungals have been shown to have antituberclear
activities [91, 105–107] and even implicated in treating latent tuberculosis as well
as decreasing the incidence of reactivation of the disease [108, 109]. These azole
antituberclear drugs are inhibitors of CYPs and in particular CYP51.These potential
new CYP inhibitors come at the cost of non-selective inhibition of human CYPs
[110, 111].
CYPs as drug targets provide a perfect opportunity to develop drugs that would
help to eradicate pathogens and disease because of their numerous pivotal homeostasis
roles within pathogens and hosts. However, the fact that organisms rely so heavily on
these essential enzymes, makes drug selectively targeting one CYP over another all the
more important. Understanding of the catalytic mechanisms of the CYP of interest is
of utmost importance in order to develop selective drugs. Studying molecular oxygen
activation in CYP51 of M. tuberculosis could result in the elucidation of diﬀerences
of catalytic mechanisms between it and other CYPs. These diﬀerences could be
exploited in developing a highly selective irreversible inhibitors in the eradication of
Tuberculosis.
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Methodology

2.1 Cloning and Site Directed Mutagenesis
2.1.1 Site Directed Mutagenesis of Mycobacterium tuberculosis CYP51
The CYP51 pET-17b plasmid, (Figure 2.1 B) was a gift from Larissa Podust of the
University of California San Fransisco. This plasmid is the expression vector used to
express the crystallized M. tuberculosis CYP51 (Mtb CYP51) [44, 105]. The CYP51
gene (Rv0764c) from the M. tuberculosis strain H37RV was initially amplified by
PCR with primers incorporating an upstream NdeI restriction site and a downstream
primer which incorporated 4 His codons, a stop codon and a HindIII restriction
site. This was amplified and cloned into the commercially available pET-17b plasmid
(Novagen) by Bellamine and coworkers [112]. This vector was used for expression and
characterization of Mtb CYP51 and later the crystal structure [113, 114]. This vector
is characterized by its T7 promoter and ampicillin resistance.
Site directed mutagenesis comprised of a polymerase chain reaction (PCR) using
primers with base pair mismatches (shown in bold and underlined) for the codons
coding for His259 and Thr260. Primers used in these reactions were,
His259Ala:
5� - GTTCGCCGGCCATGCCACCAGCTCGGG - 3� (sense)
5� -CCCGAGCTGGTGGCATGGCCGGCGAAC - 3� (antisense)
Thr260Ala:
5� - GCCGGCCATCACGCCAGCTCGGGTAC - 3� (sense)
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5� - GTACCCGAGCTGGCGTGATGGCCGGC - 3� (antisense)
Thr260Val:
5� - CGCCGGCCATCACGTCAGCTCGGGTACG - 3� (sense)
5� - CGTACCCGAGCTGACGTGATGGCCGGCG - 3� (antisense)
The setup for each PCR reaction was as follows: on ice, a 50 µL reaction was set
up using 0.5 ng of template CYP51 pET-17b , 0.5 µM of each primer, 25 µL of 2X
Phusion High Fidelity Mastermix (Thermo Scientific). Amplification conditions were
initiated with a denaturation cycle of 180 s at 371 K followed by 30 cycles at 371 K for
10 s, 25 s at 341 K and 120 s at 345 K. A final extension was carried out for 600 s at
345 K. The template DNA was then degraded by incubation of the PCR mixture with
the restriction endonuclease DpnI (New England Biolabs Inc.) (1 µL) for 1 hr at 310
K. DpnI recognizes the sequence G(m)ATC and as such will selectively target template
DNA if it has been transcribed in an organism capable of DNA methylation [115].
Each reaction was lyophilized and resuspended in a final volume of 10 µL of diH2 O.
Five microliters of each sample was analyzed by tris-acetate-EDTA gel electrophoresis
using a 1 % agarose gel matrix with ethidium bromide (0.5 µL/mL) added to the gel
(Figure 2.1 A, lane 1). Hyperladder I DNA standard (Bioline) was used to confirm
correct plasmid size (∼ 4600 bp; Figure 2.1 B) when visualized under ultra-violet light.
This visualization served to confirm suﬃcient amplification of DNA had taken place.
One microliter of the resuspended DNA was used to transform previously prepared
chemically competent DH5α Escherichia coli (E. coli). The 200 µL of cell stock was
removed from 193 K and incubated on ice with the DNA for 20 min. At this time the
cells were heat shocked by placing the cells at 277 K for 60 s, then placed on ice for
an additional 60 s. The cells were supplemented with 800 µL of Super Optimal broth
with Catabolite repression (SOC) media (which had been equilibrated to 310 K) and
then incubated at 310 K shaking at 180 RPM for 45 min. The cells were plated onto
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Lewis Broth (LB ) agar plates supplemented with 200 µg/mL of ampicillin (amp) and
incubated overnight at 310 K. Twenty colonies were picked and grown in 5 - 10 mL
of LB (200 µg/mL amp) at 310 K while shaking at 180 RPM for 12 hr. Cells were
spun down at 5000 RCF at 277 K for 10 min. The pelleted cells were lysed and the
plasmid DNA was isolated using a plasmid miniprep kit (Qiagen). The plasmids were
linearized by a 10 min digestion with Hind III (Fermentas) in the kit supplied buﬀer,
and subjected to 1 % agarose gel to confirm length and verify concentrations (Figure
2.1 A, lane 2). All plasmids were subsequently sequenced using the T7 promoter and
terminator universal primers at the Virginia Commonwealth University Nucleic Acids
Research Facilities. These universal primers also served as internal controls for the
integrity of the sequence of the T7 promoter and terminator site sequences of the
pET-17b vector. This approach aﬀorded sequencing of the CYP51 inserts in their
entirety. Plasmids with correct inserts were frozen at 253 K and stored for later use.
2.1.2 Cloning and Site Directed Mutagenesis of Trypanosoma cruzi CYP51
Previous work performed by Chen [116] had shown that expression of soluble Trypanosoma cruzi (Tc) CYP51 required truncation of the native protein and the incorporation of charged amino acid residues from the third to seventh amino acid of the
protein. The highest quality and yield of expressed protein in an E. coli expression
system was achieved when the first 21 amino acids of the native Tc CYP51 were
replaced with the sequence Met-Ala-Lys-Lys-Lys-Lys-Lys [116]. Expression of soluble
CYPs in bacterial expression systems has been problematic due to insolubility, poor
yields and inactive proteins which lead to researchers attempting to understand the
bacterial vectors as well as expression hosts. In 1990, Stewart published studies on
an E. coli expression vector which had two tac promoter cassettes [117–119]. This
pCW vector was under the control of the tryp and lac UV5 hybrid (tac) promoters
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Figure 2.1: One percent agarose gel electrophoresis A) of the site directed mutagenesis
PCR reaction (lane 1) and isolated plasmid DNA after transformation of DH5α E. coli
which had been linearized with HindIII (lane 2). M is Hyperladder I. The graphical
plasmid map of CYP51 pET-17b B) indicating the two restriction sites used to insert
the gene (NdeI and HindIII), the approximate location of the His259 Thr260 codons
in the CYP51 gene.
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[120] and included a lacI gene, a repressor that serves to inhibit expression of the
protein in the absence of an external inducer. In 1991 Barnes and co-workers [65]
used this pCW vector (referred to as pCWOri(+) hereafter) to express a recombinant
bovine microsomal 17α-hydroxylase cytochrome P450 and found as much as 16 mg/L
of culture of spectrally detectable CYP was expressed. This expression vector makes
use of an NdeI restriction enzyme site (CATATG) directly downstream of the tac
promoters, and incorporates the ATG (Met codon) initiation sequence for protein
expression.
Genomic DNA (gDNA) of the Esmaraldo strain of Trypanosoma cruzi (T. cruzi,
Tc) was a gift from Gregory Buck at Virginia Commonwealth University. A PCR
forward primer was designed to incorporate a “GC” clamp, a NdeI restriction endonuclease cut site with a Met ATG start sequence (Bold), the codons of the -Ala-Lys-LysLys-Lys-Lys- sequence (underlined) and a identical sequence to the Tc CYP51 gene
downstream of Val21
5� CGCCATATGGCTAAGAAGAAGAAGAAGAAGTCATTTAACACAACCCGTCCT
- 3�
The reverse primer similarly incorporated a “GC” clamp, a HindIII restriction endonuclease site (bold and underlined) and an antisense TGA stop codon (Bold), His6 -tag
(underlined) and the last 7 codons prior to the stop codon of the native gene
5� CGCAAGCTTCAATGATGGTGATGATGATGCGAGGGCAATTTCTTCTTGCG
- 3�
A notable consideration utilizing NdeI as the upstream restriction endonuclease site
was that the native Tc CYP51 gene was found to have an internal NdeI restriction
site approximately 1100 bp into the gene. In order to overcome this, an intermediate
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cloning step into pGEM-T easy (Promega Corp.) would have to be performed followed
by a silent mutation of the NdeI site.
Two separate PCR reactions, using diﬀerent DNA polymerases, were performed in
parallel in order to ensure that the amplified gene product would have a single 3� - A
overhang in order to be compatible with the 5� - T overhangs of the pGEM-T easy
linear vector. The two reactions were performed using either Phusion High Fidelity
DNA polymerase (Thermo Scientific) or Taq DNA Polymerase (New England Biolabs
Inc.). The Taq polymerase is used for cloning procedures requiring an 3� - A overhang
on the PCR product, however the enzymes error rate is high (285 x 10−6 ) whereas
the Phusion polymerase is a high fidelity enzyme making it 50 times less likely to
incorporate a mismatched base, but produces a blunt ended PCR product. Each
reaction was performed in order to ensure the correct outcome of the cloning procedure.
Taq polymerase reactions were performed using 150 ng of T. cruzi gDNA, 5 µL 10X
Standard Taq Reaction Buﬀer, 200 µM dNTPs, 0.1 µM of each primer, 1.25 units
of Taq DNA polymerase and sterile ddH2 O water to a final volume of 50 µL. The
temperature cycle for the reaction was as follows: a single denaturation step at 371 K
for 120 s, followed by 35 cycles of denaturation at 371 K for 45 s, annealing at 332
K for 35 s, and extension at 345 K for 90 s. The final step in an extension step at
at 345 K for 480 s. The setup for the Phusion polymerase PCR was as follows: on
ice, 150 ng of template gDNA, 0.5 µM of each primer, 25 µL of 2X Phusion High
Fidelity Mastermix (Thermo Scientific) and were made up to 50 µL with ddH2 O.
Amplification conditions were an initial denaturation cycle of 371 K for 180 s, followed
by 30 cycles of 371 K for 10 s, 332 K for 25 s and 345 K for 120 s. A final extension
was carried out for 345 K for 600 s. After the entire PCR cycle was completed 1 unit
of Taq DNA polymerase was added to the reaction and incubated at 345 K for 480
s. This step served to add a 3� - A overhang to the already amplified, blunt PCR
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product. Five microliters of each PCR reaction was analyzed by tris-acetate-EDTA
gel electrophoresis using a 1 % agarose gel matrix with ethidium bromide (0.5 µL/mL).
Hyperladder I DNA standard (Bioline) was used to confirm correct amplicon size
Figure 2.2 A, lane 1).
This visualization served to confirm suﬃcient amplification of DNA had taken
place. Contaminants in the remaining 45 µL of each reaction were removed using the
Isolate PCR kit (Bioline Inc.) so as to not influence downstream applications of the
amplified DNA, resulting in DNA of approximately 150 ng/µL suspended in ddH2 O.
By the equation:
ngV × KbI
× I : V = ngI
KbV

(2.1)

where ng is defined as nanograms, V as vector, Kb as kilobases, I as insert and I:V
as the insert to vector molar ratio, ligation reactions were prepared. Fifty nanograms
of pGEM-T easy vector (3 Kb) was used in each ligation reaction with insert:vector
ratios of 3:1, 1:1, 1:3 using 75 ng, 25 ng and 9 ng of PCR product (1.6 kB) respectively.
Ligations reactions were carried out in 10 µL volumes consisting of 5 µL of 2X rapid
ligation Buﬀer, previously calculated amounts of vector and insert, 3 Weiss units of T4
DNA ligase and ddH2 O. An amount of 0.01 Weiss units of T4 DNA Ligase is defined
as the amount of enzyme required to catalyze the ligation of greater than 95 % of the
Hind III fragments of 1 µg of Lambda DNA at 289 K in 20 minutes. The ligation
reaction was incubated at 277 K for 14 hr, after which the T4 DNA ligase was heat
inactivated at 338 K for 20 min. Three microliters of each reaction was transformed
into DH5α E. coli as in section 2.1.1 and plated onto LB agar amp(100 µg/mL) plates
which had been supplemented with 40 µL of 20 mg/mL solution of 5-bromo-4-chloro3-indolyl-β-D-galactopyranoside (X-gal) (Sigma) in dimethyl sulfoxide (DMSO) and
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40 µL of 0.1 M Isopropyl β-D-1-thiogalactopyranoside (IPTG) approximately 2 hr
prior to use. The pGEM-T easy vector is supplied as a linear fragment of DNA with
a fragment of the lacZ gene on both the 5� and 3� end. Should the linear vector
be ligated into a closed circular plasmid, the gene would be complete and would
be expressed in the presence of an inducer such as IPTG. The expressed protein,
β-galactosidase, catalyzes the degradation of X-gal resulting in colonies which are
blue in color. Successful cloning of the insert will result in an interrupted lacZ gene
with colonies being incapable of degrading X-gal ultimately resulting in white colored
colonies. This screening method, known as ”blue-white colony screening”, provides a
rough visual distinguishing feature of which colonies may potentially have the correct
insert ligated into the plasmid. White colonies were selected, grown in liquid cultures
and their plasmids isolated and sequenced using the T7 promoter and SP6 universal
primers as in section 2.1.1. Both the Taq polymerase and Phusion polymerase PCR
reactions yielded the correct insert without any mutations.
The silent mutation of the internal NdeI restriction site (sequence: CATATG)
which spanned the in-frame codons, TCA (encoding Ser357), TAT (encoding Tyr358)
and GTT (encoding Val359), was performed using site directed mutagenesis as outlined
in section 2.1.1. The codon which encodes Ser357 was an attractive candidate for the
incorporation of a silent mutation due to the fact that a single base pair mutation
(TCA to TCT) would result in the same amino acid coding while abolishing the NdeI
site. The primers used were of the sequences
sense:
5� - GAGGTCAAGGTTGGTTCTTATGTTGTTCCCAAAGG - 3�
antisense:
5� - CCTTTGGGAACAACATAAGAACCAACCTTGACCTC - 3�
where the mutated base pair is bold and the remaining sequence of the now mutated
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Nde I site is underlined. Amplification conditions was initiated with a denaturation
cycle of 371 K for 180 s, followed by 30 cycles of 371 K for 10 s, 335 K for 25 s and 345
K for 120 s. A final extension was carried out for 345 K for 600 s. This was followed
by DpnI digestion, purification and transformation of DH5α E. coli. After growth and
isolation of the plasmid, sequencing was performed using the T7 promoter and SP6
universal primers in order to confirm the single base mutation. Plasmids containing
the correct inserts were stored at 253 K until further use.
Two digestion reactions were performed in parallel using the Tc CYP51 pGEM-T
easy plasmid easy or the pCWOri(+) plasmid. In both experiments, 0.5 µg of plasmid
DNA was added to 2 µL of 10X FastDigest Green Buﬀer (Fermentas), 1 unit of HindIII
(Fermentas) and 1 unit of NdeI (Fermentas), and made up to a final volume of 20 µL
with ddH2 O. The digestion was incubated at 310 K for 10 minutes after which the
reaction was halted by direct loading of the mixture to a 1 % agarose gel matrix with
ethidium bromide (0.5 µL/mL) and performing tris-acetate-EDTA gel electrophoresis.
After suﬃcient migration of the bromophenol blue dye front of the FastDigest Green
loading dye along the gel, the gels were visualized using UV light. The DNA bands
corresponding to an approximate size of 1.5 Kb (in the digestion of Tc CYP51 pGEMT easy plasmid DNA) or 4.8 Kb [in the digestion of pCWOri(+)] was excised and
cleaned using the Isolate Gel Kit (Bioline). Care was taken so as to limit the time of
gel exposure to UV light during the visualization and band excision steps, as UV light
is capable of damaging DNA which may result in mutations. Two microliters of gel
purified DNA was once again subjected to electrophoresis and visualized, in order to
estimate DNA concentrations by relating the intensity of the purified DNA bands to
the known concentrations of the marker bands of Hyperladder I. Ligation reactions
were performed using approximately 50 ng of purified digested pCWOri(+) and either
5 ng (1:3 insert:vector ratio), 15 ng (1:1) or 45 ng (3:1) of digested Tc CYP51 as
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calculated by equation 2.1. These DNA mixtures were incubated with 1 µL of 10X T4
DNA Ligase Reaction Buﬀer (New England Biolabs Inc.), 1 unit of T4 DNA Ligase
(New England Biolabs Inc.) made up to a final volume of 10 µL with ddH2 O. One
unit of T4 DNA ligase is defined as the amount of enzyme required to ligate 50% of
HindIII fragments of λ DNA in a total reaction volume of 20 µL in 30 minutes at
289 K. Incubations were performed at room temperature for 16 hr at which time the
reaction was halted by heat inactivation of the ligase enzyme at 338 K for 20 min.
Five microliters of the ligation reaction was used to innoculate DH5α E. coli cells and
plated onto LB agar amp(100 µg/ml) plates and incubated at room temperature for
20 hr. Colonies were grown as previously described and their plasmids isolated and
sequenced in order to verify the correct inserts. Four internal primers (two sense and
two antisense) were in the sequencing reactions. The sequence of the primers were:
sense:
5� - CATTATGACTCCAGTGTTCGG - 3�
5� - CTATTCGCCGTGATCCTCCACTC - 3�
antisense:
5� - CATGGTGTGAGAGTAACGGTGAAC - 3�
5� - GGATTGCAGGGACAAAGTTCTG - 3�
Plasmids of pCWOri(+) containing the correct Tc CYP51 sequence were frozen at
253 K until further use.

2.2 Expression and Purification
2.2.1 Expression and Purification of Mycobacterium tuberculosis CYP51
Mycobacterium tuberculosis CYP51 (Mtb CYP51) and its mutants were overexpressed
and isolated from HMS174(DE3) E. coli cells. Cells were transformed with the CYP51
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Figure 2.2: Vector maps of Tc CYP51-pGEM-T easy A) and CYP51-pCWori(+)
B). One percent agarose gels indicating relative size of Tc CYP51 PCR amplicon of
approximately 1.6 Kbp C), linear Tc CYP51-pGEM-T easy D) (approximately 4.4
Kbp) and linear CYP51-pCWori(+) of approximately 6.3 Kbp E).
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pET-17b expression vector by heat shocking chemically competent cells. One µg
of isolated expression vector was incubated with 200 µL of chemically competent
HMS174(DE3) cells on ice for 30 min. After the incubation, cells were placed into
water at 315 K for precisely 60 s. Cells were then transferred back to ice for a further
60 s. Seven hundred µL of LB media (298 K) was added to the cells and placed in the
shaking incubator at 310 K and 200 RPM for 45 min. The entire culture (900 µL) was
plated onto LB-agar plates supplemented with ampicillin (200 µg/mL) and allowed to
grow at 310 K for 16 hrs. A single colony was used to inoculate 100 mL of LB media
with ampicillin (100 µL/mL) and grown overnight at 310 K and 200 RPM in the
shaking incubator. Fifteen milliliters of this overnight culture was used to inoculate
multiple 1 L batches of LB media containing 0.1 M KPhos (pH7.4) , ampicillin (100
µL/mL), and 5% glycerol (v/v) and grown at 310 K and 180 RPM. Once the OD600
had reached between 0.4 and 0.6, the temperature was decreased to 293 K (291 K for
the Thr260Val mutant ) and shaking at strictly 150 RPM. The OD600 was monitored
until it reached 0.6 - 0.8 at which time the cultures were induced with 0.2 mM IPTG
and 0.5 mM of the heme biosynthesis precursor, δ-Aminolevulinic acid (5-ALA), was
added. After 20 hr of growth, cells were harvested by centrifugation at 277 K for 10
min at 5000 RCF and stored at 193 K for later use.
Cell pellets were defrosted on ice and 3 ml of lysis buﬀer [50 mM Tris-HCl (pH 8),
500 mM NaCl, 10 % glycerol, 1mM phenylmethylsulfonyl fluoride (PMSF)] to every
gram of pellet was used to re-suspend the cells. The suspension was lysed and the
cell debris was pelleted as in Section 2.2.3. The supernatant was loaded onto Qiagen
Ni-NTA agarose resin that had been pre-equilibrated with lysis buﬀer. Once loaded,
the column was washed with 1.5 - 2 L of lysis buﬀer and protein was eluted with lysis
buﬀer with 50 mM Imidazole. All fractions containing P450 were concentrated in
Amicon filtration units with molecular weight cutoﬀ of 30 kDa. Concentrated protein
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was loaded onto a Superdex-75 column and run with buﬀer at 0.2 mL/min [50 mM
Tris-HCl (pH 8), 100 mM NaCl, 5 % glycerol]. Fractions with a A419 /A280 ratio of 1.8
was considered pure [11] and confirmed by SDS-PAGE (Figure 2.3. These fractions
were pooled and stored at 193 K until further use.
2.2.2 Expression and purification of recombinant Trypanosoma cruzi CYP51
Initial expression and purification conditions were performed following the conditions
published by Chen and coworkers in 2009 [121] and 2010 [116]. However, a combination
of these protocols resulted in the best yield of functional CYP with regards to
growth conditions, and modifications made to the protocols published in [116] were
suﬃcient to achieve homogenous protein verified by SDS-PAGE. HMS174 (DE3) E.
coli competent cell stocks were transformed with Tc CYP51 pCWOri(+) using the
previously described heat-shock method and plated onto LB Agar amp(100 µg/mL)
plates. These transformations were incubated at 310 K for 16 hr after which a single
colony was selected and used to inoculate 100 mL of LB broth supplemented with
200 µg/ml of Ampicillin. This seed culture was grown at 310 K for 12 hr shaking at
200 RPM. Fifteen milliliters of the seed culture were used to inoculate 1 L of Terrific
Broth that had been supplemented with 1 mM thiamine and 150 µg/mL ampicillin
and was grown at 310 K and 200 RPM agitation until the optical density at 590 nm
reached an absorbance of 1.0. This initial growth of the culture took approximately
6 hr. At this time the agitation was decreased to 180 RPM, the temperature was
decreased to 298 K and the cultures were induced with IPTG (final concentration of
0.2 mM) in the presence of 1 mM 5-ALA. After 40 hr cultures were centrifuged at
5000 RPM for 10 min, and the pellets were frozen at 193 K until further use.
A large scale expression (35 L) was performed using a BioFlo 510 Sterilize-InPlace 40 L Fermentor (New Brunswick Scientific) with conditions as previously
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Figure 2.3: Tris-glycine SDS-PAGE gels of A) CYP51 wild type, B) CYP51
His259Ala, C) CYP51 Thr260Ala and (D) CYP51 Thr260Val. M - Protein standard, lane 1 - flow through of the Ni2+ -NTA column, lane 2 - 1st wash, lane 3 -2nd
wash, lane 4 - elution from Ni2+ -NTA, lane 5 - Superdex 75 elution.
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described. Scaling of the reaction was performed by increasing the initial seed culture
from 100 mL to 1 L and the inoculation volume was increased from 15 mL to 1 L.
Incubation times and temperatures remained unchanged. As it has been suggested
that CYP51 expression is sensitive to excessive aeration [Larissa Podust (USFC),
private communication], the scaling of agitation of cultures on a small scale setting
(rotations of flask) to agitation by way of a propeller shaft in combination with sterile
airflow into the BioFlo 510 vessel had to be estimated. Air pressure maintained
throughout the growth at 10 lb/in2 and agitation was initially set to 200 RPM before
induction and decreased to 150 RPM after induction. Cells were pelleted as previously
described.
Cell pellets were defrosted on ice and resuspended in 3 mL of lysis buﬀer [20 mM
Tris-HCl (pH 8), 10 % glycerol, 1mM PMSF and 0.1 mM dithiothreitol (DTT)] to
every gram of cell pellet. The cell suspension was lysed by two passes through a French
pressure cell press (25 000 psi). The lysate was centrifuged at 10,000 RCF for 45 mins
at 277 K. The supernatant was passed through a CM-cellulose (Whatman) matrix
in a flow-through regime, as the protein did not bind to the matrix. The eluant was
diluted with a 5 M NaCl solution to a final NaCl concentration of 500 mM NaCl. This
was loaded directly onto a Ni-NTA gravity column. The matrix was washed with 1 L
of wash buﬀer [20 mM Tris-HCl (pH 8), 10 % glycerol, 1mM PMSF, 500 mM NaCl
and 50 mM imidazole] and protein was eluted with elution buﬀer [20 mM Tris-HCl
(pH 8), 10 % glycerol, 1mM PMSF, 500 mM NaCl and 200 mM imidazole, 0.1 mM
DTT]. The fractions with absorbance at A420 were pooled and subjected to two rounds
of 6 hr dialysis at 277 K into [20 mM Tris-HCl (pH 8), 10 % glycerol and 0.1 mM
DTT]. The NaCl-free protein dialysate was loaded onto a Fast Flow DEAE-sepharose
(Sigma) ion exchange column and eluted over a gradient from 100 mM to 500 mM
NaCl. This was analyzed for homogeneity by SDS-PAGE and protein integrity by
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UV-vis spectroscopy as seen in Figure 2.4.
2.2.3 Expression of CYP101
Wild type cytochrome CYP101 was overexpressed and isolated from E. coli transformed
with a vector containing the Psuedomonas putida strain ATCC 17453 P450cam gene
[122, 123]. The E. coli BL21 strain as well as the methodology for growth, expression
and purification of P450cam was a generous gift from Prof. John Dawson of University
of South Carolina, Columbia. An LB-agar plate supplemented with ampicillin (200
µg/mL) was streaked with colonies from freezer stocks(stored at 193 K) and incubated
at 310 K overnight. One hundred milliliters of ampicillin supplemented (100 µL/mL)
LB broth was inoculated with two colonies from the overnight plates and grown in a
shaking incubator for 6 hrs at 310 K and 200 RPM. After this growth, 4 1 L batches
of LB media supplemented with camphor (80 mg/L) and ampicillin (200 mg/L), were
inoculated with 2 mL of overnight culture. These cultures were grown at 310 K and
180 RPM in the shaking incubator for 18 hr. Cells were pelleted by centrifugation
at 277 K for 10 min at 5000 RCF and broth was discarded. Pellets were either used
immediately or frozen at 193 K until further use.
Three milliliters of lysis buﬀer [50 mM potassium phosphate (KPhos) pH 7.4,
1 mM camphor, 1mM PMSF] to every gram of pellet was used to re-suspend the
cells. Cell lysis was performed by subjecting the suspension to two passes through a
French pressure cell press (25 000 psi). The lysate was centrifuged at 277 K at 10,000
RCF for 45 mins in order to remove cell debris. The supernatant was loaded onto
a pre-equilibrated DEAE-sepharose fast flow ion-exchange column and washed with
1 L of lysis buﬀer. P450cam was eluted with a KCl gradient (50 mM to 250mM)
over 2 L of buﬀer at a flow rate of 1 mL/min and P450 containing fractions were
pooled and concentrated in Amicon filtration units with a molecular weight cut oﬀ
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Figure 2.4: A) Tris-glycine SDS-PAGE gel of T. cruzi CYP51. M - Protein standard,
lane 1 - Flow through of the Ni2+ -NTA column, lane 2 - 1st wash, lane 3 -2nd wash,
lane 4 - elution from Ni2+ -NTA, lane 5 - 10x concentrated elution from Ni2+ -NTA, 6 after dialysis, 7 - Flow through of DEAE column, lane 8 - elution from DEAE column,
lane 9 - 10x concentrated elution from DEAE column. B) Absolute UV-vis spectra of
T. cruzi CYP51, ferric (blue), ferrous (red), and carbon monoxyferrous (orange).
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of 30 kDa. P450cam was loaded onto a Superdex-75 column pre-equilibrated with
buﬀer containing 50 mM KPhos (pH 7.4), 50 mM KCl, and 1 mM camphor and run
at 0.2 mL/min. Fractions were monitored for purity by their A391 /A280 ratio, with
fractions of equal purity being pooled and either subjected to further rounds of size
exclusion chromatography (fractions with A391 /A280 ratio <1.4) or concentrated in
Amicon filter units and stored at 193 K (A391 /A280 ratio >1.4) for later use.
2.3 Protein Characterization
2.3.1 Ferric (Fe3+ ), Ferrous (Fe2+ ) and Fe2+ -CO/Fe2+ diﬀerence spectra
Characterization of P450s is primarily performed using UV-visible spectroscopy. A
dual-beam scanning spectrophotometer with a sample and reference light cells is
critical when performing diﬀerence spectra. Each protein that has been purified must
be assessed for its ability to be reduced, and whether the reduced protein is capable of
binding carbon monoxide (CO) ultimately shifting the Soret from ∼ 420 nm to ∼ 450
nm. Two reduced volume poly(methyl methacrylate) (PMMA) disposable cuvettes
were filled with 1 mL of buﬀer and were placed into the reference and sample light
chambers and a scan from 300 nm to 700 nm was taken, the spectra of which was
assigned as the baseline. In order to acquire an absolute spectra of the ferric protein 2
mL of ferric P450 (5 - 10 µM) was placed in the sample chamber and scanned over the
same wavelengths relative to the buﬀer. This protein was removed and a few crystals
of the reductant, sodium dithionite, were added to the protein and once again was
scanned relative to buﬀer in order to establish the absolute ferrous species’ spectral
properties. In order to perform a CO or P450 diﬀerence spectra, the reduced protein
was split into two cuvettes and and were loaded into both the sample and reference
cells. A scan was performed and the spectra was assigned as a baseline. CO is then
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bubbled into the protein sample in the sample chamber, for 30 - 60 s and a scan
relative to the reduced protein is performed. The ability of the protein to bind CO and
produce a Soret shift is indicative to its functionality [1, 124].The P450 concentration
was then calculated from the absorption change at 450 nm relative to the absorbance
change at 490 nm using the Beers Law equation and the extinction coeﬃcient �450−490
= 91 mM−1 · cm−1 [2].
2.3.2 Pyridine Hemochromogen
In the case of CYP51, The CO-bound complex rapidly decays (in the order of seconds)
making P450 quantification diﬃcult. It has been suggested that a suitable measure
for amount of heme containing protein is to measure the amount of heme that
complexes with pyridine in a basic environment [11]. This was performed based on
the methodology from [124]. Purified protein was made up to 2 mL total volume and
final concentration of 0.2 M NaOH and 20 % pyridine. This was split into two PMMA
cuvettes and both samples were placed into the dual beam spectrophotometer . A
baseline spectrum was recorded between 600 and 500 nm. A few crystals of sodium
dithionite were added to the sample cuvette and another spectrum was recorded.
Using the Beers Law equation and the extinction coeﬃcient �557−575 = 32.4 mM−1 ·
cm−1 , the concentration of heme can be measured [124].
2.3.3 24,25 Dihydrolanosterol Synthesis and Solubilization
Lanosterol was hydrogenated by Thuy Nguyen to 24,25-Dihydrolanosterol (DHL). The
synthesis was as follows: Lanosterol (Steraloids Inc., Newport, RI, USA) containing
55-65 % of this sterol was purified by column chromatography (silica gel, ethyl
acetate:hexane 1:4). In a Parr hydrogenator jar, a solution of lanosterol (2 mmol,
0.85 g) in dichloromethane (40 ml) was added 5 % Pd/C [20 % (w/w), 0.17 g] and
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Figure 2.5: Spectra of Ferric (blue) and ferrous (red) of CYP101 A) and CYP51
wild type B).
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hydrogenated at room temperature at 50 psi for 24 hr. The mixture was filtered
through celite, and the filter cake was washed with dichloromethane (3 x 5 ml). The
filtrate was concentrated in vacuo to aﬀord dihydrolanosterol as a white solid in
quantitative yield. 1 H NMR (400 MHz, CDCl3 ) δ 3.2 (m, 1H), 2.1-0.9 (m, 45 H), 0.8
(s, 3H), 0.7 (s, 3H).

13

C NMR (100 MHz, CDCl3 ) δ 134.5, 134.5, 79.1, 50.7, 50.6, 50.0,

44.6, 39.7, 39.0, 37.2, 36.6, 35.8, 31.2, 31.0, 29.8, 28.4, 28.2, 28.1, 28.0, 26.7, 24.4, 24.2,
23.0, 22.7, 21.2, 19.3, 18.9, 18.4, 15.9, 15.6.
This molecule is insoluble in almost all biologically compatible solvents, and was
dissolved in 100 mM Kphos (7.5) buﬀered saline, 45 % (2 - Hydroxypropyl) - β
- cyclodextrin (HPβCD) solution. Four and a half grams of HPβCD was added
incrementally to 8 mL of a stirring, refluxing solution of KPhos buﬀered saline. After
each addition of HPβCD the solution was allowed to stir until all the HPβCD had
dissolved before more was added. After all 4.5 grams of HPβCD had been added,
the solution was made up to 9.5 mL and the heat of the solution was lowered below
refluxing of the solution. DHL was then added (2.143 mg) while the warm solution was
stirring. The temperature and stirring was maintained until all DHL had dissolved ( ∼
2 hr). The solution was made up to 10 mL with diH2 O making the final concentration
of DHL 500 µM. The solution was aliquoted, lyophilized and stored at 253 K. The
lyophilized product was made up in appropriate volumes with diH2 O before use.
2.3.4 Ligand Binding Diﬀerence Spectra
Ligand binding studies were performed using 1 µM protein in a dual-beam spectrophotometer. Two milliliters of protein in 50 mM Tris-HCl (pH 8), 100 mM NaCl,
buﬀer was split into two cuvettes and placed into the sample and reference cells of
the spectrophotometer. As temperature can aﬀect binding of substrates the proteins
and ligands were allowed to equilibrate at room temperature for 20 minutes before
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spectra were recorded. An initial spectrum is recorded between 450 and 350 nm with
protein in both the sample and reference cells of the spectrophotometer and assigned as
baseline. One microliter of ligand solution was added to the sample cuvette and 1 µL
of solvent (in which the compound was dissolved) was added to the reference cuvette
and both were mixed thoroughly by pipetting. To the same cuvettes increments of
ligand/solvent are added and spectra are recorded until no increase or decrease in
spectral features are observed. Total volume of the drug/solvent added must not
be more than 2 % of the initial volume of the protein. This ensures that protein
concentration is not altered to the extent that absorbance values will be perturbed
(Beer’s law) as diﬀerence spectra such as ligand binding produce very small spectral
changes that are required to be observed. From the spectra the inverse of δA (the
diﬀerence in absorbance between the peak and the trough of the spectrum) is plotted
against the inverse of ligand concentration. Using the equation:
1
=
δA

�

Ks
δAmax

��

1
[L]

�

+

1
δAmax

(2.2)

the Ks for the ligand can be calculated, where δA is the absorbance diﬀerence between
the peak and trough of the spectra, δAmax is the final absorbance diﬀerence between
the peak and trough of the spectra and L is ligand concentration. Figures 3.4 and 3.5
in Chapter 3 show the binding data and calculated Ks for the wild type, His259Ala and
Thr260Val proteins with DHL. Figures 2.6 and 2.7 in this chapter show the binding
data and calculated Ks for the wild type, His259Ala Thr260Ala and Thr260Val
proteins using the clotrimazole.
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Figure 2.6: A) Clotrimazole B1)Clotrimazole binding diﬀerence spectra of CYP51
wild type. B2) Calculated Ks of clotrimazole for CYP51 wild type. C1)Clotrimazole
binding diﬀerence spectra of CYP51�His259Ala
� � C2)
� Calculated Ks of clotrimazole for
1
1
1
s
CYP51 His259Ala by plotting δA
= δAKmax
+ δAmax
, where δA is the absorbance
[L]
diﬀerence between the peak and trough of the spectra, δAmax is the final absorbance
diﬀerence between the peak and trough of the spectra and L is ligand concentration.
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Figure 2.7: A) Clotrimazole B1)Clotrimazole binding diﬀerence spectra of CYP51
Thr260Ala. B2) Calculated Ks of clotrimazole for CYP51 Thr260Ala. C1)Clotrimazole
binding diﬀerence spectra of CYP51�Thr260Val
� � C2)
� Calculated Ks of clotrimazole for
1
1
1
s
CYP51 Thr260Val by plotting δA
= δAKmax
+ δAmax
, where δA is the absorbance
[L]
diﬀerence between the peak and trough of the spectra, δAmax is the final absorbance
diﬀerence between the peak and trough of the spectra and L is ligand concentration.
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2.3.5 Magnetic Circular Dichroism
Magnetic Circular Dichroism (MCD) spectra was recorded on an Olis DSM 1000
circular dichrograph (CD) (Olis) using purified CYP51 and His259Ala, Thr260Ala
and Thr260Val mutants. UV-vis spectra of one milliliter of protein (of concentrations
between 1-10 µM [20mM Tris-HCl buﬀer (pH 8), 100 mM NaCl and 5% glycerol]) in
a quartz cuvette (pathlength 1 cm) were recorded in order to establish the protein
concentration in each sample using the A419 extinction coeﬃcient of 134 mM−1 .cm−1 .
The ferric protein was then placed into a 1.4 T magnetic field in the assigned north
to south orientation. Three spectra were recorded from 300 to 700 nm using a 1200
lines/mm grating and a slit width of 0.6 mm. These three spectra were averaged by the
Olis Global Works CD software to produce the assigned north spectrum. The polarity
of the magnetic field was reversed to south to north orientation and three spectra were
recorded, averaged and assigned as the south spectrum. The Olis Global Works CD
software was used to subtract the south spectrum from the north spectrum rendering
the MCD spectrum of the protein. HPβCD-DHL was then added to the protein to final
concentration of 50 µM and the MCD spectrum was recorded. The values recorded by
the CD over the 300 - 700 nm range were in the units of millidegrees. These units were
converted to mdeg.M−1 .cm−1 .T−1 , using previously calculated protein concentrations,
the magnetic field of 1.4 T and a pathlength of 1 cm.

2.4 Cryogenic Spectroscopy
2.4.1 “Freeze–Pump–Thaw” Buﬀer Degassing
When conducting experiments requiring observation of reactive oxygen intermediates
of CYPs it is necessary to remove all dissolved gases from the buﬀers being used in
the experiments. In the case of the buﬀers being used in the cryogenic experiments,
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dissolved gases such as oxygen and carbon monoxide which are known ligands of the
CYPs need to be removed. This was done using the “freeze–pump–thaw” method.
This is a three step process which is typically performed with organic solvents employed
in organic synthesis of air sensitive compounds. The freezing of the solvents eﬀectively
abolishes any evaporation during the application of vacuum. Once most of the gases
have been evacuated from the headspace, the vessel is closed to the pump and the
surrounding atmosphere, maintaining vacuum within it and the solvent is allowed
to defrost. During this step, dissolved gases will come out of solution and fill the
evacuated headspace. This cycle is repeated until all dissolved gases are removed.
Airfree Schlenk tubes were filled to half of their total volume with buﬀers glycerol
(required for the formation of an optically pure glass at cryogenic temperatures) and
were connected to a gas/vacuum manifold. In the case of CYP51 buﬀers were either
0.1 M KPhos buﬀer pH 8 for cryoradiolytic studies or 0.2 M Tris pH 8 for oxyferrous
formation, while the buﬀer for CYP101 was 0.1 M KPhos buﬀer, pH 8.0, containing 1
mM camphor. The Schlenk tubes were submerged in liquid N2 so that the surface
of the buﬀer within the tube was level with the surface of liquid N2 . Submersion of
the tubes lower than the level of liquid N2 could result in the liquefaction of gases on
the surface of the frozen buﬀer. Thirty minutes freeze time is required to suﬃciently
freeze a sample of 100 mL. After this time, the tubes were opened to the vacuum
line and the tubes were evacuated until the headspace pressure was between 50 – 100
mTorr (5 min). Tubes were then removed from liquid N2 and submerged fully in warm
water (∼318 K) until no ice was present. This cycle was repeated until the pressure
readings were identical before and after opening the Schlenk tube to the vacuum line
(4 – 5 cycles). Once suﬃcient degasification had been performed, the gas manifold was
purged with N2 and the Schlenk tubes were carefully opened to the gas line in order
to layer an inert atmosphere over the buﬀer and the glass stoppers were replaced with
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rubber septa, parafilmed, and the tubes were closed oﬀ to the gas line. Buﬀers and
glycerol were used within two days of degasification.
It is important to note that the Schlenk tubes will shatter if the buﬀers are not
suﬃciently frozen before vacuum is applied, the tubes are warmed up in air or cold
water, and the sample is not totally defrosted before freezing in the subsequent cycle.
2.4.2 Preparation of Oxyferrous Cytochrome P450
Previously purified proteins and their mutants (Section 2.2) were defrosted on ice and
concentrated to 1 – 10 µM in a total volume of 1.5 mL. In order to minimize dissolved
oxygen protein solutions were purged under N2 gas for at least 20 minutes while on
ice. The protein samples were moved to a N2 -filled glovebox where the remainder of
sample manipulations were performed. Proteins were reduced with “a few crystals” of
sodium dithionite. Any remaining dissolved oxygen will react with sodium dithionite
[125]. Oxygen levels present in protein samples that have not been purged with N2 will
result in elevated levels of sulfate and sulfite when sodium dithionite is added. These
elevated levels of sulfates and sulfites will precipitate the protein. The proteins were
incubated with sodium dithionite for 15 min on ice and removed from the glovebox in
a sealed cuvette and monitored spectroscopically between 350 and 700 nm in order
to confirm full reduction of the protein by the appropriate shift in the Soret and
charge transfer bands. Removal of excess sodium dithionite is performed using a 5 mL
G-25 Hi-Trap desalting column which had been equilibrated with 6 column volumes
of appropriate degassed buﬀer at ∼ 5 mL/min. One and a half milliliters of protein
was loaded onto the desalting column at a rate of 1 mL/min and the flowthrough
was discarded. The protein was eluted with 2 mL of buﬀer at a rate of 1 ml/min.
Plastibrand 1.5 mL polymethylmethacrylate disposable cuvettes were filled with 0.75
mL of degassed glycerol and 0.25 mL of reduced, sodium dithionite free protein or
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degassed buﬀer (blank) was added and was mixed thoroughly by gentle pipetting.
The cuvettes were sealed and parafilmed and incubated on ice for 1 hr. Addition of
oxygen was performed by bubbling oxygen gas into the cold glycerol/protein mixture
for 3 minutes after which the cuvettes were resealed and placed in liquid N2 vapors
for at least 45 min. Cuvettes were then submerged in liquid N2 and remained at
this temperature (77 K) for the remainder of the study. This method of freezing
(incubation in vapors then submersion in liquid N2 ) allows for slow and controlled
freezing of the sample in order to maintain the integrity of glycerol glass required for
optical spectroscopy. Insuﬃcient mixing of the samples would lead to“pockets” within
the glycerol/protein buﬀer matrix which are not in a 3:1 glycerol/buﬀer ratio. These
pockets will undergo phase transitions above 180 K leading to sample cracking and
which renders the prepared samples opaque and unusable. It is assumed that glycerol
does not perturb the catalytic cycle of CYP51 as previous studies use concentrations
as high as 20 % (v:v) [11, 44, 105, 126].
2.4.3 Sample Preparation for Phosphorus-32 Radiolytic Studies
A 100 mM potassium phosphate (pH 8) 90% (v:v) glycerol solution was oxygenated
by bubbling oxygen gas into the solution at ambient temperature for 25 min. To this
solution, 200 µL of

32

P-enriched orthophosphoric acid (50 mCi/mL) purchased from

Perkin-Elmer (MA, USA) was added and was supplemented with 25 µL of bovine
liver catalase, from Sigma-Alderich (∼ 1500 units) and incubated at 277 K for 1 hr.
This incubation is required for the complete elimination of H2 O2 that was generated
by the radiolytic decay of H2 O by the isotope during its transportation [127, 128].
Cooling of the oxygenated glycerol helps to minimize the autooxidation that may
occur during mixing of the reduced protein and the glycerol. Reduction of the protein
and removal of excess of sodium dithionite was performed as in 2.4.2. Samples were
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drawn into a 1 mL syringe and placed on ice within the N2 filled glovebox. The
syringes were removed from the glovebox and 300 µL of protein was injected into
the oxgenated glycerol buﬀer/32 P-enriched orthophosphoric acid/catalase solution.
This was thoroughly mixed for less than 3 minutes to minimize autooxidation of the
oxyferrous species. The samples were frozen as in Section 2.4.2 and left at 77 K for
four to six weeks.
2.4.4 UV-Visible Spectroscopy of Catalytic Intermediates
In order to record spectra at cryogenic temperatures and controlled annealing conditions, samples were housed in Janis STVP-100 Cryostat (Figure 2.8) with fused-silica
optical windows. Ten to twenty hours prior to use, the cryostat was mounted into
position within an Olis Cary-14 Spectrophotometer Conversion with a custom chamber
capable of housing the cryostat. The vacuum jacket of the cryostat was evacuated
using a Hi Cube Turbo Pump (Pfeiﬀer Vacuum). Once the cryostat jacket pressure
was between 1 and 3 e−6 mbar the cryostat was purged with either N2 or He gas for
10 min depending on what liquid cryogen was used. In each case, liquid N2 or liquid
He, the cryogen was transferred into the cryostat using the “push and pull” method
for initial cool down. An over pressure is placed on the cryogen dewar with gas and a
pump is attached to the sample tube pumping port of the cryostat, and while cryogen
is “pushed” into the cryostat by the gas over-pressure, it is also being “pulled” out by
the pump. This transfer of cryogen was maintained until the silicon diode temperature
sensors on the cryostat vaporizer was at the temperature of the respective cryogen
liquid (lN2 - 77 K, lHe - 4 K). At this point the sample tube pumping port was
closed and pressure within the cryostat was increased until the over-pressure relief
valve opened. The sample tube pumping port was then opened to atmosphere and
the cryostat was allowed to equilibrate at this temperature until the sample holder
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reached the same temperature. Samples were loaded into the custom made spring
loaded sample holder (Figure 2.8) while submerged under liquid N2 . The sample
holder was rapidly transferred to the cryostat with sample being exposed to air for
less than 2 s. All UV-vis spectroscopy at cryogenic temperatures was performed using
an Olis Cary-14 Spectrophotometer Conversion with a custom chamber capable of
housing a Janis STVP-100 cryostat. Temperature output of the Janis cryostat was
performed using a Lakeshore 332 Temperature controller. The Olis spectrophotometer
was controlled using the Olis Global Works software package.
The cryoradiolytic samples of Mtb CYP51 and its mutants were to be incubated at
77 K and the temperature gradually increased in increments of 10 K while recording
spectra, in order to evaluate the formation and decay of distinct spectroscopic species.
To evaluate the background of the glycerol buﬀer and

32

P-ortho-phosphoric acid over

the temperature range, a protein free sample was subjected to UV-vis spectroscopy
from 10 K to 120 K in order to determine a temperature specific baseline. The spectra
of the standard can be seen in Figure 2.9A. These temperature specific baselines would
reduce the noise component of the spectra when SVD analysis was performed. In
order to indirectly observe the decay of

32

P-ortho-phosphoric acid, a protein sample

was evaluated over 4 hr at 10 K. During this time, the formation of solvated electrons
can be seen as a broad peak from ∼500 nm to ∼700 nm as shown in Figure 2.9B and
is consistent with what has been observed in other studies [129]. The protein Soret is
present however the Q-bands are obscured by the broad solvated electron peak. The
solvated electrons were removed by photobleaching with a cutoﬀ filter of λ > 450 nm
[127, 130, 131] as shown in 2.9B.
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Figure 2.8: Schematic of the Janis STVP-100 Cryostat.
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Figure 2.9: A) UV-vis spectra of protein-free glycerol buﬀer standards with 32 Portho-phosphoric acid over 10 - 120 K . B) UV-vis spectrum of protein with solvated
electrons (dotted orange) and the same sample photobleached for 30 mins (blue).
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2.5 Stopped Flow UV-visible Spectroscopy
2.5.1 Buﬀer Preparation
Fifty millimolar Tris-HCl (pH 8) buﬀer was degassed as in Section 2.4.1 and was
bubbled with oxygen for approximately 30 min. The dissolved oxygen was found to
be approximately 900 µM using a dissolved oxygen water quality test kit available
from LaMotte. The principles of the test are based upon an azide modification of the
Winkler method for determining dissolved oxygen [132, 133]. Essentially this method
is performed as a titration resulting in a visible colorimetric change of the solution.
The first step of the oxygen determination is the dropwise addition of MnSO4 followed
by the dropwise addition of KOH to the buﬀer being tested resulting in a Mn(OH)2
precipitate:

MnSO4 + 2KOH → Mn(OH)2 + K2 SO4

(2.3)

This precipitate is oxidized by dissolved oxygen present, forming a brown precipitate
[Mn(OH)3 ] by the reaction:

Mn(OH)2 + O2 + 2H2 O → 4Mn(OH)3

(2.4)

Sulfuric acid is added converting the hydroxide to a sulfate which is then soluble:

2Mn(OH)3 + 3H2 SO4 → Mn2 (SO4 )3 + 6H2 O

(2.5)

At this stage known quantities of buﬀer and reagents are used in order to accurate
quantify the amount of oxygen present. Twenty milliliters of the previously manipulated buﬀer is measured to which 250 µL of starch indicator solution (with KI) is
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added in a dropwise manner resulting in a blue color.

Mn2 (SO4 )3 + 2KI → 2MnSO4 + K2 SO4 + I2

(2.6)

sodium dithionite is then added in a measured dropwise manner, and is the final
titration step that results in the solution turning to a colorless solution. With the
known amount of added sodium dithionite, the dissolved oxygen can be calculated in
parts per million and converted to molarity.

2Na2 S2 O3 + I2 → Na2 S2 O6 + 2NaI.

(2.7)

2.5.2 Decay rates of Oxyferrous CYP51
CYP51 wild type, mutants, P450cam and Ligand solutions were defrosted on ice and
purged under an atmosphere of N2 for 20 min. After purging the samples and ligands,
each was sealed and transferred to an N2 -filled glovebox. Each protein sample was
reduced with a few crystals of sodium dithionite and allowed to at room temperature.
A 5 mL G-25 desalting column was equilibrated with 5 volumes of degassed buﬀer at a
flow rate of 5 mL/min and 1.5 mL of reduced protein was loaded. The excess sodium
dithionite is removed as 1.5 mL of protein is eluted from the column at 1 mL/min.
GE Lifesciences instructs to collect 2 mL of eluate, however it was found that 2 mL
of eluate will still contain excess sodium dithionite, whereas 1.5 mL does not. The
protein is then diluted to 3 mL with degassed buﬀer and split in two and DHL-HPβCD
was added to one (final concentration 50 µM). The reduced protein (with and without
ligand) was taken up in a 10 mL syringe and placed in sealable Ziploc ® bag purged
with N2 and sealed. Three milliliters of degassed buﬀer that had been oxygenated
(2.5.1) was taken up in 2 10 mL syringes (ligand was added to a final concentration
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of 50 µM in one of the syringes). Each syringe was allowed to equilibrate to room
temperature for 15 minutes. All stopped flow measurements were performed using an
Applied Photophysics SX-18MV stopped flow UV-visible spectrophotometer with a
photodiode array detector and the associated Acorn PC with X-Scan software (Applied
Photophysics) allowed for multiple wavelength absorption spectra to be acquired. The
dead time of the machine is approximately 2 ms. After flushing with degassed buﬀer,
the stopped flow apparatus was loaded with 1.5 mL of oxygenated buﬀer and 1.5 mL
of protein. The machine was baselined with oxygenated buﬀer. Each syringe was set
to drive 175 µL (total mixing volume of 350 µL) and 400 scans/second were performed
for 2 seconds. Data sets were analysed using Pro-K software (Applied Photophysics)
perfoming Singular-Value-Decomposition (SVD) and global fit in order to reconstruct
single data sets and the rates of formation or decay of particular species.
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The Role of the Acid-Alcohol Pair in Mycobacterium tuberculosis CYP51
Oxyferrous Formation and Stability

3.1 Introduction
In order to fully understand the catalysis of a particular cytochrome P450, it is
important to characterize each intermediate in the catalytic cycle (Scheme 1.1).
Characterization of some intermediates pose diﬃculties due to their transient lifetimes.
The oxyferrous state of CYP101 has been well characterized using a number of
spectroscopic techniques including UV-vis [134], magnetic circular dichroism (MCD)
[135] Mössbauer [136] and resonance Raman [13, 14]. This oxygen intermediate is
considered to be the last “easily” characterizable intermediate of the CYP catalytic
cycle. As much of this work has been performed with CYP101, CYPs capable of
catalyzing reactions that diverge from classical CYP hydroxylation such as the C-C
bond cleaving enzymes may not adhere to the same catalytic intermediates. The
characterization of the oxyferrous intermediate, its formation as well as its decay, in a
particular enzyme is important as it represents the first step in the process of oxygen
activation. Oxygen activation in CYP51 catalysis is of particular interest owing to the
fact the enzyme is capable of tuning its reactivity solely on the basis of its activation
and stabilization of oxygen intermediates.
The oxyferrous species is common to all CYP reactions, regardless of their end
point and is the critical intermediate that will undergo one electron reduction to
form a peroxo-anion adduct. This adduct represents a branch point in the catalysis
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of C-C cleaving CYPs. It can either be protonated to ultimately generate Cmpd I
or participate directly as a nucleophile. The commitment to one of these pathways
depends on how the active site environment tunes proton delivery to the peroxoanion
intermediate. The axial thiolate ligand of the CYPs as well as reduction of this
oxyferrous species will result in oxygen-oxygen bond scission active heme-oxidant
capable of substrate oxidation [1].
The characterization of the oxyferrous species of CYPs has led to elaborate studies
in which this intermediate is reduced [15, 127]. This one electron reduction of the
oxyferrous intermediate generates intermediates which do not accumulate to an extent
that they may be detected on an appreciable timescale and hence have to be trapped
in matrices at cryogenic temperatures. Due to the transient lifetimes of oxygen
intermediates, their experimental observation can be performed using one of two
approaches. These are techniques capable of detecting intermediates on a short
timescale or methods requiring low temepratures to stabilize otherwise short lived
intermediates.
In this study rapid-scanning stopped-flow UV-vis spectroscopy is used in order
to measure the rates of formation and decay of the oxyferrous intermediate in wild
type Mtb CYP51 and its mutants. In order to understand and characterize oxygen
intermediates within Mtb CYP51 and its mutants, it was critical to investigate the
kinetics of oxygen binding and release. These studies demonstrate the role of the
His-Thr dyad in binding of oxygen and stability of oxyferrous CYP51.
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3.2 Results and Discussion
3.2.1 UV-vis and Magnetic Circular Dichroism
A description of the methods for expression and preliminary characterization of
Mtb CYP51 and the His259Ala, Thr260Ala and Thr260Val mutants are described
in Chapter 2. Ferric and ferrous absolute UV-vis spectra of the wild type protein
(Figures 3.1B) were consistent with previously reported spectra [11,112] of this protein.
The UV-vis spectrum of the ferric wild type protein spectrum has a Soret at 419 nm
with charge-transfer bands (Q-bands) at 535 nm (β band) and 571 nm (α band) as
well as a smaller peak at 363 nm. The absolute ferrous spectrum of the wild type
protein shows a red-shifted Soret to 424 nm with two smaller peaks at 530 nm and 559
nm. Each mutant shared the same features as the wild type CYP51 in their ferric and
ferrous spectra (Figures 3.2 B). The carbon monoxyferrous complex was consistently
unstable in all proteins. A representive spectrum illustrating a decrease of the Soret at
449 nm, with concomitant increase of a peak at 420 nm over time shown in Figure 3.3
which occurs over a minute or so. This CO-adduct collapse has been shown to occur
at a slower rate (4x) in the prescence of estriol [11], however this was not observed
in the presence of 50 µM of DHL although this was not further investigated. As no
major diﬀerences in these spectra were observed, it was assumed that the mutations
did not drastically change the resting state, oxidation states and CO binding of the
proteins.
As the endogenous substrate of Mtb CYP51 is unknown, it was decided to proceed
with the mammalian CYP51 substrate dihydrolanosterol (DHL) as a ligand for further
studies. DHL binding to Mtb CYP51 produces a“Type 1” binding spectra which
is characteristic of a peak at ∼390 nm and a trough at ∼420 nm. Figures 3.4 and
3.5 show the DHL binding data and calculated Ks for the wild type, His259Ala and
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Figure 3.1: Spectra of Ferric (blue) and ferrous (red) of CYP101 A) and CYP51
wild type B).
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Figure 3.2: Spectra of Ferric (blue) and ferrous (red) Mtb CYP51 His259Ala A),
CYP51 Thr260Ala B), CYP51 Thr260Val C)
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Figure 3.3: A) A time scan of Mtb CYP51 wild type Fe2+ -CO/Fe2+ diﬀerence spectra.
(B) CYP51 His259Ala (blue) CYP51 Thr260Ala (purple) and CYP51 Thr260Val (red)
Fe2+ -CO/Fe2+ diﬀerence spectra.
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Thr260Val proteins. The calculated Ks of DHL binding to the wild type protein
was 0.2 µM which is slightly lower than the 1 (± 0.5) µM reported by Bellamine
[112]. Both His259Ala and Thr260Val showed a higher Ks for DHL during binding
studies with 0.43 and 1.2 µM respectively. Both of these mutants also showed a
much greater absorbance in their ligand binding diﬀerence spectra with the A390
(indicative of HS) being ∼5 and ∼20 times greater than wild type in the His259Ala
and Thr260Val mutants respectively. This may be due to these mutations increasing
the hydrophobicity of the active site making it more likely for DHL to bind and
displace the co-ordinated H2 O. In the case of Thr260Val mutant this could also be
due to the fact that this mutation would remove a hydrogen bonding site capable
of stabilizing the heme co-ordinated H2 O molecule. However the Thr260Ala mutant
shows no significant spin shift on the addition of DHL, even when concentrations as
high as 5 µM of ligand was added (data not shown). This suggests that either DHL
does not bind, or when the DHL binds to the active site it does not displace the heme
co-ordinated H2 O molecule shifting the spin state from low to high spin.
3.2.2 Magnetic Circular Dichroism
In order to understand the population of spin states of the heme prosthetic group in
each protein in the presence and absence of DHL, MCD spectra were recorded. If
performed in the UV-vis region of heme (300 - 700 nm) the MCD spectra is capable of
revealing the spin state of the ferric CYP. Initial spectra were recorded with CYP101
in the presence and and absence of camphor. These spectra are illustrated in Figure
3.6 and spectra features are recorded in Table 3.1 and represent the low spin (Figure
3.6 A) and high spin (Figure 3.6 B) states of CYP101. These spectra can be used as a
comparison in determining the spin state populations in CYP51 wild type and mutants.
The spectra of CYP51 wild type illustrated in Figure 3.7 A and Table 3.1 showing
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Figure 3.4: A) Dihydrolanosterol B1)Dihydrolanosterol binding diﬀerence spectra of CYP51 wild type. B2) Calculated Ks of DHL for CYP51 wild type.
C1)Dihydrolanosterol binding diﬀerence spectra of CYP51
His259Ala
C2) Calcu�
�� �
1
1
1
s
lated Ks of DHL for CYP51 His259Ala by plotting δA
= δAKmax
+ δAmax
, where
[L]
δA is the absorbance diﬀerence between the peak and trough of the spectra, δAmax is
the final absorbance diﬀerence between the peak and trough of the spectra and L is
ligand concentration.
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Figure 3.5: A) Dihydrolanosterol B1)Dihydrolanosterol binding
diﬀerence
�
� � � spectra
1
Ks
1
1
of CYP51 Thr260Val. B2) Calculated Ks by plotting δA = δAmax
+ δAmax
,
[L]
where δ A is the absorbance diﬀerence between the peak and trough of the spectra,
δAmax is the final absorbance diﬀerence between the peak and trough of the spectra
and L is ligand concentration.
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peaks at 358 nm, 411 nm and the crossover at 420 nm. Additional bands are found at
428 nm, 522 nm, 562 nm, 579 nm. These peaks when compared to that of CYP101
and P450LM-2 are consistent with a hexacoordinated low spin state of the enzyme
[137–140]. On the addition of saturating concentrations of substrate, the spectrum of
wild type protein did not significantly change, confirming the results of UV-vis ligand
titration studies. The His259Ala mutant in the absence of substrate showed nearly
identical peaks as that of the low spin wild type protein (Figure 3.7 B). In saturating
concentrations of substrate, evidence of a slight trough at 396 nm is present. Although
the amplitude of this trough is not great and other spectral features are missing, it is
evident of a small population of the protein being in the pentacoordinated high spin
state as seen in CYP101[141], P450terp [137] and chloroperoxidases [142]. The MCD
spectra of both the Thr260Ala (Figure 3.8 A) and Thr260Val (Figure 3.8 B) mutants
are slightly red shifted relative to that of the wild type protein as is shown in Table
3.1. Although the shift of these peaks is not indicative of spin state, they provide
insight into the active site environment. On the addition of substrate to the Thr260Ala
mutant, no distinct spectral changes are seen in the MCD spectrum. This confirms
UV-vis ligand binding studies and strengthens the argument that the Thr260Ala
mutant does not bind DHL. The MCD spectrum of Thr260Val however shows the
most dramatic change of all the proteins used in the study. The troughs appearing at
396 nm, 553 nm and 655 nm (slight) are all indicative of a pentacoordinated high spin
protein [137, 141, 142]. Although some of the low spin spectral features are present, a
large proportion (60 %) of the protein is in the high spin state as confirmed by UV-vis
ligand titration data.
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Figure 3.6: MCD Spectra of A) ligand free low-spin CYP101 and B) High spin
CYP101 in the presence of camphor (100 mM)
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Figure 3.7: MCD Spectra of A) Mtb CYP51 wild type and B) His259Ala mutant in
the absence (red) and presence of DHL (50 µM)
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Figure 3.8: MCD Spectra of A) Thr260Ala and B) Thr260Val mutant in the absence
(red) and presence of DHL (50 µM)
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Table 3.1: Soret MCD Spectral Features of CYP101 and Mtb CYP51 proteins
Protein

Spectral bands, nm

CYP101

356

412

418(0)

428

464

523

563

579

CYP101 + Cam

394

-

414(0)

420

-

532

555

656

WT CYP51

358

411

420.5(0)

428

465

522

562

579

WT CYP51 + DHL

358

411

420.5(0)

428

465

522

562

579

His259Ala

358

411

421(0)

430

465

524

562

579

His259Ala + DHL

356

411

422(0)

429

464

524

562

579

Thr260Ala

365

412

425(0)

434

473

529

563

581

Thr260Ala + DHL

365

412

425(0)

434

473

529

563 581

Thr260Val

362

410

422(0)

433

471

525

564

581

Thr260Val + DHL

354

414

423(0)

432

478

531

566

581

3.2.3 Oxygen Binding Kinetics
In order to understand the role of the acid-alcohol pair of Mtb CYP51 plays in O2
binding and stability, double mixing stopped flow was performed. Ferrous CYP51
in anaerobic buﬀer was rapidly mixed with oxygenated buﬀer and 800 spectra were
recorded over ∼2 seconds. This was suﬃcient time to observe the oxyferrous intermediate form and decay to the ferric form by the equation:

k

k

1
2
F e2+ + O2 −
→
F e2+ O2 −
→
F e3+ + O2 −.

(3.1)

Where k1 is the pseudo-first order rate constant of oxygen binding to form the
oxyferrous intermediate and k2 is the rate constant for the autoxidation of oxyferrous
to ferric protein and the release of the superoxide anion. Initial experiments were
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performed with CYP101 in the presence of camphor as shown in Figure 3.9. The
formation of oxyferrous is observed with a Soret at 421 nm which was consistent
with literature [134, 143]. This peak at 421 nm decreased time dependently with the
increase of a peak at 391 nm indicative of CYP101 in the ferric HS state. In order
to decompose the raw time course data into basis spectra of individual components,
SVD analysis was performed using the Pro-K software (Applied Photophysics). SVD
analysis generated up to 8 principal components, however as only three distinct
spectral species were expected (by equation 3.1), the three most relevant spectral
components were selected for further analysis. These principal components were then
used to perform a global fit, and reconstitute calculated spectra. This was performed
by fitting the spectral components to a 3 component model i.e. A → B → C. Using
this information as well as the starting concentration of the protein, three basis spectra
and their concentration profiles are illustrated in Figures 3.9 B and C respectively.
Experimentally, 800 spectra were recorded over 236 s. As oxyferrous formation in
CYP101 is so rapid, the first scan of the mixing experiment was unable to record pure
ferrous CYP101. During SVD analysis and global fit, the ferrous species was of too
low a concentration to calculate a spectrum and hence is not shown in Figures 3.9 B.
The calculated k1 for this reaction was 2.2 µM−1 .s−1 which is comparable to
literature values of 1.7 µM−1 .s−1 [144, 145]. The autoxidation rate (k2 ) was calculated
to be 0.006 s−1 at 298 K. This is consistent with literature values for CYP101 of
0.004 s−1 measured at 293 K [146] and 0.0043 s−1 measured at 296 K [143]. The
reproduction of the published rate constants validated this approach in our hands.
Figure 3.10A shows the time profile of the mixing of ligand free ferrous Mtb CYP51
wild type with oxygenated buﬀer. The first and last scan over a two second timescale
show spectral features features consistent with ferrous and ferric CYP51 wild type
respectively. As no distinct oxyferrous species was observed over this timescan, SVD
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Figure 3.9: A)Stopped flow spectra over 236 seconds of CYP101 at 298 K. B)
Invdividual components from the calculated spectra of global fit of SVD analysis
where the blue spectrum is the ferric high spin and orange is the oxyferrous state of
CYP101. C) The concentration profiles of each of the calculated spectra over time.
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Table 3.2: Rate Constants of Oxyferrous Formation and Oxidation in CYP51 proteins
- DHL

+ DHL (50 µM)

Protein

k1

k2

k1

k2

WT CYP51

63.1(±3.6)

2.1(±0.1)

15.3(±0.9)

2.6(±0.1)

His259Ala

35.7(±3.8)

2.0(±0.1)

67.85(±1.3) 1.8(±0.1)

Thr260Ala

30.9(±4.6)

3.4(±0.5)

31.6(±3.4)

2.9(±0.1)

Thr260Val

16.2(±2.6)

2.5(±0.4)

32.0(±5.6)

7.3(±1.3)

Where k1 (units µM−1 .s−1 ) is the rate constant for binding of oxygen to
the ferrous species and k2 (units s−1 ) is the autoxidation of the oxyferrous
species to the ferric protein. Bracketed values represent the standard
deviations of three repeated mixing experiments of the same conditions.
analysis was performed as previously described. Using this information as well as the
starting concentration of the protein, three spectral species are illustrated in Figure
3.10 B. The calculated spectra of the oxyferrous species was slightly blue shifted in its
Soret (422 nm) when compared to the ferrous Soret (424 nm). The charge transfer
bands of the oxyferrous species overlapped that of the peaks seen in the spectrum
of the ferrous species. This spectrum of the oxyferrous species was confirmed by
cryogenic oxyferrous formation (Chapter 4). All the rate constants for the wild type
and each mutant protein in the absence and presence of substrate are shown in Table
3.2. The rate constant k1 for oxygen binding to the ferrous enzyme was 63.1 µM−1 .s−1
and k2 for the autoxidation of the oxyferrous species was 2.2 s−1 (Table 3.2).
The rate constants for oxygen binding (k1 ) to the ferrous wild type protein is
decreased by approximately four fold in the presence of saturating concentrations of
DHL as shown in Table 3.2. The rate of autoxidation or k2 however is not changed
in the presence of ligand. In the case of the His259Ala mutant, k1 is just over half
the rate of the wild type enzyme and the rate of autoxidation is unaﬀected by this
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Figure 3.10: A)Stopped flow spectra over 2 seconds of CYP51 wildtype at 298 K.
B) Invdividual components from the calculated spectra of global fit of SVD analysis
where the blue spectrum is the ferric low spin, the red is ferrous and orange is the
oxyferrous state of CYP51 wild type. C) The concentration profiles of each of the
calculated spectra over time .

87

Figure 3.11: A)Stopped flow spectra over 2 seconds of CYP51 wildtype in the
presence of 50 µM DHL at 298 K. B) Invdividual components from the calculated
spectra of global fit of SVD analysis where the blue spectrum is the ferric low spin,
the red is ferrous and orange is the oxyferrous state of CYP51 wild type. C) The
concentration profiles of each of the calculated spectra over time .
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mutation. However in the presence of DHL the His259Ala mutant shows a k1 of 67.85
µM−1 .s−1 which is approximately four fold higher than the rate constant of the wild
type protein with ligand. The rate of autoxidation in this mutant is also not aﬀected
by DHL being present. The Thr260Val mutant shows a decreased rate constant of
oxygen binding almost 4 times slower than that of the wild type and half that of the
His259Ala mutant, but without significant diﬀerence in the autoxidation rate constant.
Substrate bound Thr260Val showed a two fold increase in k1 to 32.0 µM−1 .s−1 but
showed a 3 fold increase in the rate constant of autoxidation. The Thr260Ala mutant’s
rate constants were similar to that of the His259Ala mutant. As there is evidence
that the Thr260Ala mutant does not bind DHL, it would be expected that the rate
constants for this mutant would not change in the presence of substrate, which was
the case.
Comparing the wild type protein in the presence of DHL to CYP101 in the presence
of camphor (1 mM), wild type CYP51 has an oxygen binding rate constant of 15.3
µM−1 .s−1 at 298 K, and CYP101 has an oxygen binding rate constant of 1.7 µM−1 .s−1
[144, 145]. The diﬀerence between ligand free and ligand bound forms of the wild type
protein may be due to the ligand partially shielding the active site. In the absence of
ligand Mtb CYP51 shows a much quicker autoxidation rate in comparison to CYP101
(0.014 s−1 ) [146]. Mtb CYP51 has a much slower rate constant for this substrate-free
autoxidation however, when compared to CYP3A4 (100 s−1 ) [23]. What is consistent
between CYP101 and CYP3A4 is that in the presence of ligand, the rate constant
for autoxidation, is increased by 3 - 8 fold. This is however not the case when when
comparing the autoxidation rate constants of wild type CYP51 protein in the substrate
bound and substrate free forms.
The His259 in Mtb CYP51 is similar to to Asp251 in CYP101 as it plays the role
of the acid, in the conserved acid-alcohol pair. The fact that the ferrous form of the
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His259Ala mutant shows a slower rate in oxygen binding implies that it would have
a slower turnover of product if this is the rate determining step. The Asp251Asn
mutant of CYP101 was shown to decrease the turnover rate of NADH however the
mutant still retained the ability to hydroxylate substrate [57, 147]. This decreased
turnover of NADH was attributed to the retarded rate of ferrous formation of the
Asp251Asn mutant, and not oxygen binding to the ferrous form. The rate of oxygen
binding however is decreased in this mutant of CYP101 by almost half [57] in the
presence of camphor. This is in contrast to the His259Ala mutant which shows an
accelerated rate constant by almost four times when compared to wild type in the
presence of DHL. Under the same conditions there is slight decrease in autoxidation
rate (1.8 s−1 ) in the His259Ala mutant compared to wild type (2.6 s−1 ).
The Thr260Ala mutant shows comparable oxygen binging rate constants to the
His259Ala mutant in the absence of ligand with a slight increase in autoxidation
rate (3.4 s−1 for Thr260Ala) relative to wild type (2.1 s−1 ) and His259Ala (2.0 s−1 )
mutants. This is comparable to the Thr252Ala mutation of CYP101 however the
rate of autoxidation in this mutant was almost an order of magnitude greater in the
mutant [148]. It is thought that the Thr252 in CYP101 forms a hydrogen bond to the
bound oxygen and stabilizes this state [46, 149]. The data with regards to Thr260Ala
of CYP51 supports that this mutant does not bind to DHL.
The Thr260Val mutant shows a four fold decrease in oxygen binding rate relative
to wiltype in the absence of substrate, however there is no major diﬀerence in the
autoxidation rates. In the presence of ligand however, the Thr260Val mutant behaves
as expected with regards to autoxidation rates relative to the wild type protein when
compared to the Thr252Ala and Thr252Val mutants in of CYP101. That is, this
mutation would have an increased rate of autooxidation. The Thr260Val mutant’s rate
of autoxidation was almost three fold higher than that of the wild type (7.3 s−1 vs 2.6
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Figure 3.12: A)Stopped flow spectra over 2 seconds of CYP51 His259Ala at 298 K.
B) Invdividual components from the calculated spectra of global fit of SVD analysis
where the blue spectrum is the ferric low spin, the red is ferrous and orange is the
oxyferrous state of CYP51 His259Ala. C) The concentration profiles of each of the
calculated spectra over time .
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Figure 3.13: A)Stopped flow spectra over 2 seconds of CYP51 His259Ala in the
presence of 50 µM DHL at 298 K. B) Invdividual components from the calculated
spectra of global fit of SVD analysis where the blue spectrum is the ferric low spin,
the red is ferrous and orange is the oxyferrous state of CYP51 His259Ala. C) The
concentration profiles of each of the calculated spectra over time .
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Figure 3.14: A)Stopped flow spectra over 2 seconds of CYP51 Thr260Ala at 298 K.
B) Invdividual components from the calculated spectra of global fit of SVD analysis
where the blue spectrum is the ferric low spin, the red is ferrous and orange is the
oxyferrous state of CYP51 Thr260Ala. C) The concentration profiles of each of the
calculated spectra over time
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Figure 3.15: A)Stopped flow spectra over 2 seconds of CYP51 Thr260Ala in the
presence of 50 µM DHL at 298 K. B) Invdividual components from the calculated
spectra of global fit of SVD analysis where the blue spectrum is the ferric low spin,
the red is ferrous and orange is the oxyferrous state of CYP51 Thr260Ala. C) The
concentration profiles of each of the calculated spectra over time .
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Figure 3.16: A)Stopped flow spectra over 2 seconds of CYP51 Thr260Val at 298 K.
B) Invdividual components from the calculated spectra of global fit of SVD analysis
where the blue spectrum is the ferric low spin, the red is ferrous and orange is the
oxyferrous state of CYP51 Thr260Val. C) The concentration profiles of each of the
calculated spectra over time
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Figure 3.17: A)Stopped flow spectra over 2 seconds of CYP51 Thr260Val in the
presence of 50 µM DHL at 298 K. B) Invdividual components from the calculated
spectra of global fit of SVD analysis where the blue spectrum is the ferric low spin,
the red is ferrous and orange is the oxyferrous state of CYP51 Thr260Val. C) The
concentration profiles of each of the calculated spectra over time .
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s−1 ) and those of the Thr252Ala and Thr252Val mutants of CYP101 were almost 10
times higher than that of the wild type [46]. This implies that in the presence of DHL,
the oxyferrous form of Mtb CYP51 might be stabilized through an interaction between
Thr260 and the iron-bound dioxygen. Potentially Thr260 is positioned so that it may
interact with the iron-bound peroxide in the peroxo intermediate of the wild-type
enzyme. Potentially the presence of substrate is suﬃcient to disrupt the hydrogen
bonding water network so that in the absence of the Thr260 hydroxyl group, the
oxyferrous rapidly autoxidizes. In the absence of ligand, O2 may not have a hydrogen
bond from the Val residue, however the remaining volume of the active site may be
filled with water for hydrogen bonding. Addition of DHL may displace this water
and abolish any potential hydrogen bond interactions, eﬀectively destabilizing the
oxyferrous complex.
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In situ Generation of Early Oxygen Intermediates in Mycobacterium
Tuberculosis CYP51

4.1 Introduction
The oxyferrous intermediate of Mtb CYP51 had previously been observed and characterized by stopped flow UV-vis spectroscopy, in Chapter 3 at 298 K. This previous
work established an important experimental platform in order to study more reactive
intermediates intermediates of the CYP catalytic cycle. In vivo, the reduction of the
oxyferrous species results from the transfer of an electron from a ferredoxin. In most
CYPs, this reduced oxyferrous species does not accumulate in ambient temperatures.
Cryogenic trapping is one tool that can be utilized to isolate, directly observe and
characterize these transient species. Cryogenic trapping of catalytic intermediates
requires a protein to be trapped in a matrix in a manner akin to isolating organic
molecules in frozen noble gases [150, 151] at very low temperatures (between 4 K 77 K). Cryogenic matrix isolation studies of enzymes are not new, as spectroscopic
techniques such as electron paramagnetic resonance (EPR) and Mössbauer make use
of cryogenic temperatures.
Optical spectroscopy such as UV-vis requires the trapping of an enzyme in a
transparent matrix in the wavelength range used in the experiment. Many solvents have
been exploited in order to attain an optically transparent “glass” at low temperatures,
ranging from methylcyclopentane, to ethanol and boric acid [152]. The requirements
of the solvent used in these studies are, they must be non-denaturing and cause very
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little if any, perturbation to the protein. Ethylene glycol, trehalose and glycerol
have also been used for low cryogenic trapping of proteins [153]. Glycerol solutions
in a ratio of >65% (w/w) were shown to be adequate to inhibit a process of water
crystallization which causes a phase separation ultimately destroying the sample’s
optical transparency [154].
The process of cryogenically trapping CYP catalytic intermediates relies on the
process of stabilizing these intermediates for an appreciable timescale at temperatures
low enough for there to be insuﬃcient energy to overcome the energetic barrier
of the intermediates decay. Generating these intermediates, in particular the one
electron reduced oxyferrous species, requires a cryoreduction technique. Essentially,
the oxyferrous intermediate must be formed at ambient temperatures (277 K) in
order to be experimentally feasible, after which this intermediate must be frozen (77
K) at which point a cryoradiolytic technique can be used in order to reduce this
intermediate. Cryoradiolytic techniques can employ a number of methods in order
to reduce the trapped oxyferrous species. These include irradiating samples with
high-energy photons such as a X-rays, gamma rays from

60

Co [15, 130, 155], or

32

P

[127, 155, 156]. The latter can be added to the sample as which can be conveniently
added to the sample in the form of 32 P-ortho-phosphoric acid to aﬀord in situ radiolysis.
The cryoradiolytic technique generates intermediates in situ while the protein
is trapped within a frozen matrix. Other techniques such as rapid scanning UVvis stopped flow are able to observe more stable catalytic intermediates as well.
However they require elaborate machinery, that will allow for mixing of multiple
buﬀers (oxygenated versus deoxygenated) and proteins (CYP and ferredoxin) in order
reconstitute the catalytic cycle. It is because of these reasons as well as its relative
ease in generating and stabilizing these intermediates that makes cryoradiolysis an
indispensable technique. Isolating the reduced oxygen intermediates is critical in the
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understanding of which catalytic intermediates may be stabilized by CYP51 during
its catalysis and under which conditions these intermediates are present if we are to
fully understand the mechanism by which CYP51 promotes C-C cleavage.
After this cryoradiolytic reduction, the newly formed intermediates will be stable
at 77 K. Spectroscopic characterization of these intermediates can then take place. In
this study, proteins were reduced in an oxygen free environment to form the ferrous
species. After excess reductant was removed, the ferrous protein was mixed with
oxygenated glycerol and

32

P-ortho-phosphoric acid in order to form the oxyferrous

intermediate. These samples were frozen at 77 K and left untouched for four weeks
at at this temperature. This four week incubation of the oxyferrous protein with
32

P-ortho-phosphoric acid was suﬃcient to allow in situ radiolysis to occur. After

this incubation, the samples were subjected to UV-vis spectroscopy and temperature
annealing experiments were performed. Temperature annealing is the raising of
the temperature in increments and at each temperature, spectra are recorded. The
catalytic intermediates and their stability are dependent on temperature, hence as
temperature is raised, intermediates will decay and new intermediates will form. This
decay and formation of new intermediates can be monitored spectrscopically.
With the previously characterized oxyferrous intermediate of Mtb CYP51 and
its mutants described in Chapter 3 further studies at cryogenic temperatures were
performed to capture and characterize reduced dioxygen intermediates in wild type
and mutant CYP51.
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4.2 Results and Discussion
4.2.1 UV-visible spectroscopy of Oxyferrous Intermediates at Cryogenic Temperatures
Exploiting the handful of literature describing radiolytic reduction of CYP101, we
aimed to reproduce these observations to evaluate our experimental approach. CYP101
served as a convenient standard for which to compare our cryogenic studies for several
reasons. First, oxyferrous CYP101 can be prepared in high yield and is stable at 277
K. Second, there are easily recognizable diﬀerences in the Soret bands of CYP101
species. Three experimental reactions were set up, to evaluate varying conditionsin
collecting UV-vis spectra at low temperature. The ferric, ferrous and oxyferrous states,
would allow for observation of any perturbations that could occur as a result of low
temperatures as well as the increased concentrations of glycerol, when compared to
those performed at ambient temperatures. As shown in Figure 4.1 A, the three distinct
spectral signatures are apparent for ferric, ferrous and oxyferrous. The ferric spectra
is identical to that of CYP101 in the high spin state at ambient temperatures, with a
Soret at 393 nm and a weak band at 645 nm. As with the ferrous spectra, a Soret at
410 nm and a shoulder at 543 nm were as expected [127, 157, 158]. The oxyferrous
species showed a Soret at 417 nm a weak band at 351 nm and a peak at 553 nm
which as previously reported are all spectral features of CYP101 in the oxyferrous
state [127, 157, 158]. The spectral characteristics of these states of CYP101 were
indicative of the fact that minor if any perturbations occurred under the conditions
of high concentrations of glycerol, and temperatures below 77 K. The stability of
the CYPs at 77 K is critical for the generation of reduced oxyferrous species. It is
known that certain proteins may undergo cold denaturation [159,160]and these studies
served to confirm the absence of this denaturation The incubation of protein with
32

P-ortho-phosphoric acid would have to be performed at 77 K for four weeks at a
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time for there to be suﬃcient isotope decay in order for cryoradiolysis to occur.
As with CYP101, the ferric, ferrous and oxyferrous states of Mtb CYP51 and its
mutants were prepared, each in the presence and absence of 50 µM DHL. Results of
each spectra recorded (Figures 4.2, 4.3, 4.4 and 4.5) were consistent with previously
recorded spectra at ambient temperature as well as the basis spectra of the oxyferrous
spectra from Chapter 3. With only slight shifts in (< 2 nm) peaks being seen, which
when taking into consideration the wavelength intervals of the stopped flow instrument
was 2 nm is within the resolution of the instrument.
4.2.2 Reduced Oxyferrous Intermediates and Temperature Annealing
Following our success in capturing oxyferrous CYP101, we adapted the in situ cryoradiolysis technique using 10 mCi of

32

P-ortho-phosphoric acid to reduce oxyferrous

CYP101. Incubation of these samples took place for up two 6 weeks but no less than
four weeks at 77 K. Previous work performed by Denisov using a

60

Co had shown

that 4-5 Mrad was suﬃcient to reduce the oxyferrous of species of CYP101 [130]. The
addition of 10 mCi of

32

P-ortho-phosphoric acid would be equivalent to 3.5 Mrad

during its first half-life (342 hr or ∼2 weeks). This incubation was suﬃcient to yield a
species with Soret at approximately 440 nm at 77 K as shown in Figure 4.1 B. This
440 nm Soret is characteristic of the hydroperoxo species as confirmed by Denisov and
coworkers [127, 130].
The intermediates generated by cryoradiolytic reduction of wild type Mtb CYP51
after four weeks of incubation shows a split Soret at approximately 421 nm and 442
nm seen in Figure 4.6 C, with α-band at 565 nm and 531 nm. When comparing this
to CYP101, the newly formed peak at 442 nm is distinctly red shifted from that of the
oxyferrous complex in both proteins. The peak at 442 nm in Mtb CYP51 wild type is
speculated to be either the ferric-peroxo or ferric-hydroperoxo species as seen in the
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Figure 4.1: A)UV-vis spectra of Ferric, Ferrous and Oxyferrous CYP101 at 77 K.
B) UV-vis spectra of CYP101 at 77 K after four weeks of incubation with 32 P-orthophosphoric acid at 77 K
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Figure 4.2: A)UV-vis spectra of Ferric, Ferrous and Oxyferrous CYP51 wild type at
77 K. B) UV-vis spectra of Ferric, Ferrous and Oxyferrous CYP51 wild type at 77 K
in the presence of 50 µM DHL
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Figure 4.3: A)UV-vis spectra of Ferric, Ferrous and Oxyferrous CYP51 His259Ala
at 77 K. B) UV-vis spectra of Ferric, Ferrous and Oxyferrous CYP51 His259Ala at 77
K in the presence of 50 µM DHL
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Figure 4.4: A)UV-vis spectra of Ferric, Ferrous and Oxyferrous CYP51 Thr260Ala
at 77 K. B) UV-vis spectra of Ferric, Ferrous and Oxyferrous CYP51 Thr260Ala at 77
K in the presence of 50 µM DHL
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Figure 4.5: A)UV-vis spectra of Ferric, Ferrous and Oxyferrous CYP51 Thr260Val
at 77 K. B) UV-vis spectra of Ferric, Ferrous and Oxyferrous CYP51 Thr260Val at 77
K in the presence of 50 µM DHL
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Figure 4.6: UV-vis spectra of Mtb CYP51 wild type, His259Ala and Thr260Ala at
10 K after four weeks of incubation with 10 mCi of 32 P-ortho-phosphoric acid.
optical spectra of CYP101 [16, 127, 130]. The broader peak at 421 nm is speculated as
being a mixture of ferric and ferrous protein, based on the rapid autoxidation that
may have occured in Mtb CYP51 on the addition of ferrous protein to oxygenated
buﬀer.
After decreasing the temperature from 77 K to 4 K followed by annealing the
temperature upward in increments of 10 K, the 442 nm peak begins to decrease at
temperatures above 160 K and is no longer present at 180 K (Figure 4.7 A). As the
442 nm peak decreases there is an increase in a peak at 419 nm consistent with the
formation of low spin ferric Mtb CYP51. SVD Analysis of annealed spectra, yields a
basis spectra with a distinct Soret at 442 nm (Figure 4.7 B) consistent with literature
[127] for a peroxo species. Conclusive assignment of this species will require an
orthogonal spectroscopic method such as resonance Raman or electron paramagnetic
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resonance. The optical spectra of the hydroperoxo and peroxo species are said to
be only 2-3 nm apart in their Sorets [16, 17]. The peroxo and hydroperoxo species
have been confirmed in CYP101 by EPR [15, 161] and resonance Raman [17] studies
using the same cryoradiolytic techniques. Through the means of EPR it was seen that
the Asp251Asn mutant of CYP101 was able to form the peroxoanion and through
annealing of the sample formed the hydroperoxo species which decayed to ferric species
on further annealing [15, 17, 162]. The Asp251Asn mutant of CYP101 is unable to
transfer protons to the peroxoanion and hence at lower cryogenic temperatures there
is no formation of hydroperoxo.
The His259Ala mutant of Mtb CYP on initial inspection shows characteristics of
the wild type protein with a split Soret at 441 nm and 418 with Q-bands at 562 nm
and 531 nm (Figure 4.8. Although the Soret of this mutant is slightly blue shifted, 441
nm (His259Ala) vs 442 nm (wild type), this may be a result of a number of population
of states. However after annealing and SVD analysis, two spectra of interest are found.
As shown in Figure 4.8 B, the basis spectra results show very similar spectra with two
diﬀerent Sorets, one at 441 nm and the other at 439 nm. Although small, the blue
shift of the Soret by 2 nm may be indicative of a protonation step that is occurring as
temperature is increased. The role of the His259 is thought to be similar to that of
Asp251 of CYP101, and as such may be important in proton transfer. In the wild
type protein at 77 K during cryoradiolysis, the protonation of the peroxoanion species
may be barrier-less or at least occur a time scale shorter than the 4 week incubation
period. This would result in only one state being observed, that of hydroperoxo. In
the His259Ala mutant, the proton transfer may be disrupted which would result in
the accumulation of the peroxoanion species. In the Asp251Asn CYP101 mutant the
peroxo species is stable between 77 K and 120 K and as the temperature is raised
above this point, the peroxo species is protonated. This was observed using EPR
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[15] as well as resonance Raman [17], where the protonated and unprotonated states
are unambiguous in their spectra. As with the Asp251Asn mutant of CYP101, the
His259Ala mutant of CYP51 may exhibit this protonation when temperature is raised
(although not directly observed in the optical spectra). At lower temperatures the
His259Ala mutant may form the peroxoanion species and as temperature is increased,
the lack of the His in this position might not hinder the protonation of the peroxoanion
species from another source such as active site water molecules. This speculation
could be made based on the SVD basis set of the annealing of this His259Ala sample
showing two peroxo species (Figure 4.8 B).
The Thr260Ala mutant exhibited a similar spectrum to that of the wild type with
peaks appearing at the same wavelengths as that of the wild type protein (419 nm,
441 nm, 531 nm and 562 nm) as seen in Figure 4.9 A. Temperature annealing of the
sample and subsequent SVD analysis and spectrum calculation exhibited results much
like that of the wild type protein (Figure 4.9 B). Although this mutation occurs in
the active site and plays a role in oxyferrous stability, its role in peroxo intermediate
formation and stabilization is unclear although does not inhibit the formation of such
a species. From the SVD basis spectra, and based on the Soret of shown in Figure 4.9
B as well as the similarities of the spectra to the wild type protein, the intermediate
seen is assumed to be the peroxoanion species.
4.2.3 Reduced Oxyferrous Intermediate Formation at 4 K
The previous annealing studies were performed by allowing the radiolytic process to
occur over a 4 week period at 77 K. As previous work in CYP101 has shown by other
spectroscopic techniques such as EPR [15] and resonance Raman [17] the peroxoanion
species will accumulate at temperatures below 70 K but above this temperature would
slowly decay and essentially not be detectable above 147 K when annealed [127]. It
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Figure 4.7: Annealing of cryoreduced CYP51 wild type from 10 K - 160 K in 10 K
increments A) and SVD basis spectra B)

111

Figure 4.8: Annealing of cryoreduced CYP51 His259Ala from 10 K - 160 K in 10 K
increments A) and SVD basis spectra B)
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Figure 4.9: Annealing of cryoreduced CYP51 Thr260Ala from 10 K - 160 K in 10 K
increments A) and SVD basis spectra B)
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became evident that an incubation at 10 K at the start of the cryoradiolysis would
yield insight into which peroxo species was being formed in the Mtb CYP51 wild
type protein. The radiolytic decay was monitored for 36 hrs in order to observe
the formation of the reduced oxyferrous intermediate shown in Figure 4.10 A. These
results showed a slight shoulder at 441 nm, the same as at 77 K (Figure 4.10 A). SVD
analysis of this step, where time is used as the third dimension instead of temperature,
a species with a Soret at 441 nm is observed (Figure 4.10 B). CYP101, whose catalysis
is thought to be entirely Cmpd I mediated, is capable of stabilizing the peroxoanion
at temperatures lower than 70 K. This would imply that the species formed at 10 K in
Mtb CYP51 is the peroxoanion and not hydroperoxo as the final catalytic step involved
in C-C bond cleavage is mediated by this intermediate and not hydroperoxo. If this is
indeed what is occuring it would stand to reason that the peroxoanion is stable at
temperatures higher than that of CYP101 wild type and the spectrum observed at 77
K and above is that of the peroxoanion. This is supported by the observation of the
accumulation of peroxoanion in CYP19, another C-C cleaving enzyme, whose catalytic
mechanism is also thought to be peroxoanion mediated [163]. In CYP19, Gantt and
coworkers also observed that the peroxoanion intermediate is accumulated at 77 K and
is stable to temperatures above 180 K. At which point no accumulation of hydroperoxo
species is seen [163]. This is significant in that CYP19 is capable of stabilizing the
peroxoanion intermediate at temperatures of which there is no accumulation of the
peroxoanion in CYP101. Since the proposed reactive intermediate of CYP19 mediated
C-C cleavage is the peroxoanion, the ability of the enzyme to stabilize this intermediate
strengthens the argument of its mechanism.
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Figure 4.10: A)Time course over 36 hrs of cryoreduction of Mtb CYP51 wild type
at 4 K. B) SVD basis spectra of the cryoradiolytic time course.
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Conclusion

The cytochromes P450 can be considered some of the most versatile biological catalysts.
These monoxygenases play critical roles in the metabolism of xenobiotics and in the
biosynthesis of physiologically important molecules. Although there is a postulated
and generalized catalytic cycle of these enzymes, the catalytic mechanisms of individual
CYPs can vary significantly from another due to the myriad of reactions catalyzed by
the CYP superfamily. As CYP101 was the first easily expressed CYP, the vast majority
of studies pertaining to CYPs and their catalytic intermediates have been based on
this enzyme. Unfortunately, the catalytic mechanism of this relatively “simple” model,
can not always be generalized to all members of the CYP superfamily. Being unique in
their catalytic mechanisms, the C-C bond cleaving enzymes and in particular CYP51
from Mycobacterium tuberculosis are thought to be capable of utilizing diverse catalytic
intermediates. During the process of C-C cleavage, CYP51 will perform two passes of
the catalytic cycle resulting in two straight forward hydroxylation reactions, but on
a third pass is capable catalyzing the C-C cleavage through a catalytic intermediate
which is not the classical Cmpd I. This implies CYP51 is capable of tuning its active
site in order to use multiple reactive oxygen species in catalysis. CYP51 is also
distinct from most CYPs owing to the fact that the acid functionality of the conserved
acid-alcohol pair found in most CYPs, is instead a His. This study aimed to trap
and characterize dioxygen reactive intermediates, and elucidate the role of the unique
acid-alcohol pair in the formation and stabilization of these intermediates.
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5.1 The Role of the Acid-Alcohol Pair in Mycobacterium tuberculosis
CYP51 Oxyferrous Formation and Stability
To date, no reported studies have been performed on the formation and characterization of oxygen intermediates in Mtb CYP51. In order to characterize reactive oxygen
intermediates of Mtb CYP51, the isolation and characterization of the oxyferrous
intermediate was necessary. This characterization was performed using stopped flow
rapid scanning UV/Vis spectroscopy studies on Mtb CYP51 wild type and His259Ala,
Thr260Ala and Thr260Val mutants in the presence and absence of saturating concentrations of DHL. In the absence of substrate the rate constants for binding of oxygen
to the wild type ferrous protein is faster than that of the mutants. Oxyferrous stability
however, is not altered between the wild type and the mutants. In the presence of
saturating concentrations of substrate, the wild type protein shows a two fold decrease
in the oxygen binding rate constant, however both the His259Ala and Thr260Val
mutant show a two fold increase in their oxygen binding rate constants. The rate
constants of autoxidation in the wild type and His259Ala mutant are unaﬀected by
the presence of substrate. This is not the case in Thr260Val, where the auto-oxidation
rate constant is tripled. Potentially on the binding of substrate, the lack of a suitable
hydroxyl group destabilizes the oxyferrous intermediate, increasing the enzymes rate of
uncoupling. Unfortunately the inability of the Thr260Ala mutant to bind the substrate
used in the studies could not confirm whether the increased rate of autoxidation was
as a result of a lack of a hydroxyl group, or that the Val side chain induced enough of
a conformational change within the active site to result in increased uncoupling of the
catalytic cycle.
As this studied employed the rapid mixing of the reduced CYP protein with
oxygenated buﬀer in order to observe the rates of oxyferrous formation and decay,

117
future studies could include the mixing of the ferric protein in the presence of oxygen,
with its reduced ferredoxin. As studies have shown in some cases the associated redox
partner of a CYP is capable of influencing the electron transfer, oxygen binding as
well as oxyferrous stability. This experiment would help highlight the roles of the
ferredoxin as well as the acid-alcohol pair of Mtb CYP51 in the reduction of the
protein from ferric to ferrous, the binding of oxygen to the ferrous protein as well
as the auto-oxidation of the oxyferrous intermediate. Another study that could help
understand the role of protonation of the His259 residue and its role during catalysis,
particularly in the early stages of the catalytic cycle would be pH dependent studies
where oxyferrous formation is monitored at pHs above and below the pKa of the
His259.
This study reports the successful use of stopped-flow rapid-scanning spectrophotometry in order to observe the formation and decay of the important oxyferrous
bound form of Mtb CYP51 and its His259Ala, Thr260Ala and Thr260Val mutants, in
the presence and absence of substrate, for the first time.

5.2 In situ Generation of Early Oxygen Intermediates in Mycobacterium
Tuberculosis CYP51
The cryogenic trapping of oxygen intermediates was performed in this study. The
characterization of the oxyferrous intermediates at cryogenic temperatures of each
protein in the presence and absence of substrate was in agreement with the calculated
spectra of the oxyferrous intermediate observed in the stopped flow studies. The
ability to isolate the oxyferrous intermediate as well as its stability at 77 K was critical
in order to perform cryoradiolytic studies.
The cryoradiolytic technique performed in the absence of substrate yielded the
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distinct formation of a red shifted Soret (in agreement with the literature) which
was the result of a reduced oxyferrous intermediate (either the ferric peroxoanion or
the ferric hydroperoxo intermediate). This peak was seen to decay in all mutants
between the temperatures of 160 K and 170 K. The optical spectra of the two peroxo
intermediates are almost indistinguishable except for a slight (2-3 nm) blue shift
in the Soret of the ferric peroxoanion as it is protonated to the ferric hydroperoxo
intermediate. In CYP101 this lack of a blue shift in Soret of the wild type protein is due
to the very small energetic barrier associated with the protonation of the peroxoanion,
resulting in only an accumulation of the hydroperoxo intermediate at the temperature
of 77 K. The peroxoanion however would accumulate in when cryoradiolysis was
performed at 6 K [15]. CYP19, another C-C bond cleaving enzyme thought to utilize
a peroxoanion catalytic intermediate, is capable of accumulating the peroxoanion
at 77 K which decays at temperatures above 160 K without the accumulation of
hydroperoxo. This provides support that intermediate accumulating in Mtb CYP51
could in fact be the peroxoanion intermediate. Further evidence to support this
fact would be that the same visible spectrum was calculated when the formation of
the reduced oxyferrous intermediate was generated over 36 hr at 10 K. Annealing
experiments of the reduced oxyferrous intermediate in the His259Ala mutant yielded
two distinct spectra indicating a slight blue shift in the Soret (of approximately 2
nm). The two Soret peaks correspond to that of the intermediate observed in the wild
type protein and a Soret which is blue shifted. This could imply that the His259Ala
mutant is capable of stabilizing the peroxoanion intermediate but not over the entire
temperature range used during the annealing step. As the temperature is increased,
there is a protonation of the peroxoanion to form the hydroperoxo, which as the
protein is further annealed will decay to form the ferric protein.
The inability to unambiguously assign which reduced oxyferrous intermediate was
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present in each protein will direct future studies to include resonance Raman and
EPR spectroscopy to be performed on each sample. All three techniques will be able
to distinguish which reduced oxyferrous species is present in Mtb CYP51 and its
mutants. As this data was generated with proteins in the absence of substrate, a more
relevant study would include the presence of substrate, which may act to stabilize
particular intermediates especially since diﬀerent substrate intermediates are present
during each turn of the CYP51 catalytic cycle. Substrates can include DHL as well as
the aldehyde intermediate of DHL. The aldehyde intermediate of DHL is the substrate
of the final turn of the catalytic cycle of Mtb CYP51, which is implicated in utilizing
the peroxoanion as its catalytic intermediate.

5.3 Implications
This study showed the ability to generate, stabilize and characterize reactive dioxygen
intermediates in Mtb CYP51. As the life-time of the oxyferrous intermediate in
Mtb CYP51 is extremely short at ambient temperatures, this work has shown the
laboratory’s expertise in being able to generate reduced oxyferrous intermediates at
cryogenic temperatures. These intermediates have only been generated in a handful of
Cytochromes P450 and as such this work adds critical information to the small body
of work currently reported.
This work highlighted chemical and biophysical properties of the Mtb CYP51
catalytic cycle, giving insight into the catalytic mechanism which could be used
to rationalize properties of other C-C bond cleaving enzymes. This is critical as
the catalytic mechanisms of relatively “simplistic” monoxygenating enzymes such
as CYP101 can not be generalized to the C-C bond cleavage step of enzymes such
as CYP51 and CYP19. The fact that CYP51 is a target of available drugs in the
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treatment of diseases such and Chaga’s disease as well as Anti-fungal agents, highlights
the importance of understanding the catalytic intermediates of these enzymes. The
understanding of the catalytic mechanism of Mtb CYP51 is not only important in the
fact that it can give insight into other C-C bond cleaving enzyme catalysis, but could
be used to develop highly selective and irreversible inhibitors in the treatment and
eradication of Tuberculosis.
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